OAK BLUFFS

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>			
Male	2.66	1	NC*	Male	1.32	0	NC*	
Female	1.09	3	NC*	Female	1.11	3	NC*	
Total	3.74	4	NC*	Total	2.43	3	NC*	
Brain and Cen	<u>tral Nervous S</u>	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>			
Male	0.87	1	NC*	Male	0.47	0	NC*	
Female	0.86	2	NC*	Female	0.48	0	NC*	
Total	1.73	3	NC*	Total	0.95	0	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>		
Male	0.14	0	NC*	Male	1.91	0	NC*	
Female	16.28	20	123	Female	1.88	0	NC*	
Total	16.42	20	122	Total	3.79	0	NC*	
Cervix Uteri			Oral Cavity and Pharynx					
				Male	1.74	0	NC*	
Female	0.97	2	NC*	Female	0.84	1	NC*	
				Total	2.58	1	NC*	
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	7.03	4	NC*					
Female	7.30	5	68	Female	1.93	2	NC*	
Total	14.33	9	63					
Esophagus			<u>Pa</u>	ancreas				
Male	0.89	0	NC*	Male	0.96	3	NC*	
Female	0.37	0	NC*	Female	1.15	1	NC*	
Total	1.25	0	NC*	Total	2.11	4	NC*	
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	0.39	0	NC*	Male	15.81	8	51 #-	
Female	0.31	0	NC*					
Total	0.70	0	NC*					
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>				
Male	1.50	2	NC*	Male	1.17	0	NC*	
Female	0.99	0	NC*	Female	0.79	1	NC*	
Total	2.49	2	NC*	Total	1.96	1	NC*	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	0.95	4	NC*	Male	0.56	1	NC*	
Female	0.28	0	NC*					
Total	1.23	4	NC*					
Leukemia			<u>T</u>	<u>hyroid</u>				

Male	1.03	2	NC*	Male	0.24	0	NC*
Female	0.82	2	NC*	Female	0.66	0	NC*
Total	1.85	4	NC*	Total	0.90	0	NC*
Liver and Intra	hepatic Bile I	<u>Uteri, Corpus and Uterus, NOS</u>					
Male	0.43	0	NC*				
Female	0.22	1	NC*	Female	3.09	2	NC*
Total	0.64	1	NC*				
Lung and Bron	<u>chus</u>		<u>A</u> l	ll Sites / Ty	pes		
Male	8.53	5	59	Male	52.25	32	61 ~-
Female	6.52	8	123	Female	51.79	55	106
Total	15.05	13	86	Total	104.04	87	84

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

OAKHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>v</u>		$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>			
Male	0.96	1	NC*	Male	0.53	1	NC*	
Female	0.28	0	NC*	Female	0.40	0	NC*	
Total	1.23	1	NC*	Total	0.93	1	NC*	
Brain and Cent	<u>ral Nervous S</u>	d Nervous System Multiple Myeloma						
Male	0.38	0	NC*	Male	0.17	0	NC*	
Female	0.31	0	NC*	Female	0.13	0	NC*	
Total	0.69	0	NC*	Total	0.30	0	NC*	
Breast			<u>N</u>	on-Hodgkin's	s Lymphoma	<u>1</u>		
Male	0.05	0	NC*	Male	0.77	1	NC*	
Female	5.13	6	117	Female	0.54	0	NC*	
Total	5.18	6	116	Total	1.32	1	NC*	
Cervix Uteri			<u>O</u>	ral Cavity an	d Pharynx			

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Male	0.69	0	NC*
Female	0.40	0	NC*	Female	0.25	1	NC*
				Total	0.94	1	NC*
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	2.54	1	NC*				
Female	1.82	2	NC*	Female	0.65	2	NC*
Total	4.36	3	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.33	0	NC*	Male	0.36	0	NC*
Female	0.09	0	NC*	Female	0.29	0	NC*
Total	0.43	0	NC*	Total	0.65	0	NC*
Hodgkin's Dis	<u>ease</u>		<u>Pı</u>	<u>rostate</u>			
Male	0.19	0	NC*	Male	5.57	5	90
Female	0.15	0	NC*				
Total	0.34	0	NC*				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	0.59	0	NC*	Male	0.42	0	NC*
Female	0.30	0	NC*	Female	0.20	1	NC*
Total	0.88	0	NC*	Total	0.62	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.36	0	NC*	Male	0.29	0	NC*
Female	0.09	0	NC*				
Total	0.45	0	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	0.43	0	NC*	Male	0.11	0	NC*
Female	0.28	0	NC*	Female	0.29	0	NC*
Total	0.71	0	NC*	Total	0.40	0	NC*
Liver and Intra	<u>ahepatic Bile D</u>	ucts		<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.16	1	NC*				
Female	0.06	0	NC*	Female	0.94	0	NC*
Total	0.22	1	NC*				
Lung and Bron			· · · · · · · · · · · · · · · · · · ·	ll Sites / Typ			
Male	3.17	5	157	Male	19.52	16	82
Female	1.85	1	NC*	Female	15.54	13	84
Total	5.03	6	119	Total	35.06	29	83

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

ORANGE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		$\underline{\mathbf{Exp}}$	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	5.27	6	114	Male	2.75	2	NC*	
Female	2.01	2	NC*	Female	2.30	3	NC*	
Total	7.29	8	110	Total	5.05	5	99	
Brain and Cent	<u>ral Nervous S</u>	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	1.90	0	NC*	Male	0.95	0	NC*	
Female	1.80	0	NC*	Female	0.90	2	NC*	
Total	3.70	0	NC*	Total	1.85	2	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>ı</u>		
Male	0.28	0	NC*	Male	4.00	1	NC*	
Female	32.13	41	128	Female	3.62	5	138	
Total	32.42	41	126	Total	7.61	6	79	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	3.62	2	NC*	
Female	2.11	2	NC*	Female	1.64	1	NC*	
				Total	5.26	3	NC*	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	14.05	14	100					
Female	13.43	16	119	Female	3.92	2	NC*	
Total	27.48	30	109					
Esophagus			<u>Pa</u>	ancreas				
Male	1.81	1	NC*	Male	1.97	4	NC*	
Female	0.67	2	NC*	Female	2.12	0	NC*	
Total	2.48	3	NC*	Total	4.09	4	NC*	
Hodgkin's Dise	ease			<u>rostate</u>				
Male	0.89	0	NC*	Male	32.18	36	112	
Female	0.74	1	NC*					
Total	1.63	1	NC*					
Kidney and Re	<u>nal Pelvis</u>		<u>St</u>	omach_				
Male	3.15	3	NC*	Male	2.31	3	NC*	
Female	1.92	0	NC*	Female	1.47	1	NC*	
Total	5.07	3	NC*	Total	3.78	4	NC*	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	1.98	2	NC*	Male	1.29	0	NC*
Female	0.54	1	NC*				
Total	2.52	3	NC*				
Leukemia			<u>T</u>	<u>iyroid</u>			
Male	2.20	4	NC*	Male	0.53	1	NC*
Female	1.71	2	NC*	Female	1.49	2	NC*
Total	3.91	6	153	Total	2.02	3	NC*
Liver and Intr	ahepatic Bile I	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
Male	0.89	0	NC*				
Male Female	0.89 0.41	0 0	NC* NC*	Female	6.01	13	216 #+
				Female	6.01	13	216 #+
Female	0.41 1.30	0	NC* NC*	Female		13	216 #+
Female Total	0.41 1.30	0	NC* NC*			13 108	216 #+
Female Total Lung and Bro r	0.41 1.30 nchus	0	NC* NC* <u>A</u> l	ll Sites / Ty	<u>pes</u>		210
Female Total Lung and Bron Male	0.41 1.30 nchus 17.63	0 0 22	NC* NC* <u>Al</u> 125	ll Sites / Ty Male	<u>pes</u> 107.18	108	101

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

ORLEANS

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urinaı	rinary Melanoma of Skin							
Male	9.10	13	143	Male	3.88	8	206	
Female	3.29	3	NC*	Female	2.86	13	454 ^+	
Total	12.39	16	129	Total	6.74	21	312 ^+	
Brain and Cent	Brain and Central Nervous System			Multiple Myeloma				
Male	2.34	1	NC*	Male	1.60	2	NC*	
Female	2.26	3	NC*	Female	1.44	1	NC*	
Total	4.60	4	NC*	Total	3.05	3	NC*	
Breast			No	on-Hodgkin's	s Lymphoma	a		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	0.46	1	NC*	Male	5.65	4	NC*
Female	45.01	67	149 ~+	Female	5.41	7	129
Total	45.47	68	150 ~+	Total	11.05	11	100
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx	•	
				Male	5.23	6	115
Female	2.27	3	NC*	Female	2.39	3	NC*
				Total	7.62	9	118
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	24.15	29	120				
Female	22.37	30	134	Female	5.19	9	173
Total	46.52	59	127				
Esophagus			<u>Pa</u>	ancreas			
Male	2.88	3	NC*	Male	3.22	0	NC*
Female	1.12	1	NC*	Female	3.47	2	NC*
Total	4.00	4	NC*	Total	6.69	2	NC*
Hodgkin's Dis	<u>ease</u>		<u>Pı</u>	<u>rostate</u>			
Male	0.78	0	NC*	Male	56.47	67	119
Female	0.64	0	NC*				
Total	1.41	0	NC*				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	4.76	9	189	Male	3.91	2	NC*
Female	2.80	1	NC*	Female	2.45	3	NC*
Total	7.57	10	132	Total	6.36	5	79
<u>Larynx</u>			Te	<u>estis</u>			
Male	3.05	5	164	 Male	0.87	0	NC*
Female	0.78	0	NC*				
Total	3.83	5	131				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	3.06	3	NC*	Male	0.56	0	NC*
Female	2.27	3	NC*	Female	1.47	1	NC*
Total	5.34	6	112	Total	2.03	1	NC*
Liver and Intra	ahepatic Bile	Ducts	<u>U</u> 1	teri, Corpus	and Uterus	, NOS	
Male	1.38	2	NC*				
Female	0.63	1	NC*	Female	8.64	9	104
Total	2.01	3	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	28.83	30	104	Male	173.37	198	114
Female	18.64	27	145	Female	146.68	204	139 ^+
Total	47.48	57	120	Total	320.05	402	126 ^+

 $\mathbf{Exp} = \text{expected case count}$, based on the Massachusetts average age-specific incidence rates for this cancer $\mathbf{Obs} = \text{observed case count}$

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

OTIS

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>v</u>		<u>M</u>	elanoma of S	<u>Skin</u>				
Male	0.70	1	NC*	Male	0.40	1	NC*		
Female	0.22	1	NC*	Female	0.29	0	NC*		
Total	0.93	2	NC*	Total	0.69	1	NC*		
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>				
Male	0.28	0	NC*	Male	0.13	0	NC*		
Female	0.22	0	NC*	Female	0.10	0	NC*		
Total	0.50	0	NC*	Total	0.23	0	NC*		
Breast			No	on-Hodgkin's	s Lymphoma	<u>1</u>			
Male	0.04	0	NC*	Male	0.56	0	NC*		
Female	3.95	6	152	Female	0.42	1	NC*		
Total	3.99	6	151	Total	0.98	1	NC*		
<u>Cervix Uteri</u>		Oral Cavity and Pharynx							
				Male	0.54	1	NC*		
Female	0.28	0	NC*	Female	0.20	0	NC*		
				Total	0.73	1	NC*		
Colon / Rectum	_		<u>O</u>	<u>vary</u>					
Male	1.87	2	NC*						
Female	1.47	0	NC*	Female	0.49	1	NC*		
Total	3.34	2	NC*						
Esophagus			<u>Pa</u>	ncreas					
Male	0.26	0	NC*	Male	0.27	1	NC*		
Female	0.07	0	NC*	Female	0.23	0	NC*		
Total	0.33	0	NC*	Total	0.50	1	NC*		
Hodgkin's Dise	<u>ease</u>	<u>Prostate</u>							
Male	0.13	0	NC*	Male	4.03	4	NC*		
Female	0.10	0	NC*						
Total	0.23	0	NC*						

Kidney and Rei	nal Pelvis		Stomach					
Male	0.45	0	NC*	Male	0.31	0	NC*	
Female	0.22	0	NC*	Female	0.16	1	NC*	
Total	0.67	0	NC*	Total	0.48	1	NC*	
<u>Larynx</u>			<u>T</u>					
Male	0.28	1	NC*	Male	0.19	0	NC*	
Female	0.07	0	NC*					
Total	0.35	1	NC*					
Leukemia			<u>Tl</u>	<u>ıyroid</u>				
Male	0.31	0	NC*	Male	0.08	0	NC*	
Female	0.20	0	NC*	Female	0.20	0	NC*	
Total	0.51	0	NC*	Total	0.28	0	NC*	
Liver and Intra	hepatic Bile D	<u>ucts</u>	<u>U</u> 1	teri, Corpus	ri, Corpus and Uterus, NOS			
Male	0.12	0	NC*					
Female	0.05	0	NC*	Female	0.73	1	NC*	
Total	0.17	0	NC*					
Lung and Brono	<u>chus</u>		<u>A</u>]	All Sites / Types				
Male	2.38	2	NC*	Male	14.38	15	104	
Female	1.42	1	NC*	Female	11.95	13	109	
Total	3.80	3	NC*	Total	26.32	28	106	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

OXFORD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>v</u>		$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>		
Male	7.90	8	101	Male	4.39	7	160
Female	3.06	4	NC*	Female	3.81	3	NC*
Total	10.96	12	110	Total	8.20	10	122

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Brain and Cent	ain and Central Nervous System Multiple Myeloma						
Male	3.08	5	162	Male	1.43	3	NC*
Female	2.93	5	171	Female	1.37	2	NC*
Total	6.01	10	166	Total	2.81	5	178
Breast			<u>N</u>	on-Hodgkin	's Lymphon	<u>1a</u>	
Male	0.43	0	NC*	Male	6.34	2	NC*
Female	51.62	41	79	Female	5.65	7	124
Total	52.05	41	79	Total	11.99	9	75
Cervix Uteri			<u>o</u>	ral Cavity a	nd Pharynx	_	
				Male	5.74	12	209 #+
Female	3.62	5	138	Female	2.60	3	NC*
				Total	8.34	15	180 #+
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	21.02	14	67				
Female	20.23	20	99	Female	6.38	4	NC*
Total	41.25	34	82				
Esophagus				ancreas			
Male	2.79	4	NC*	Male	2.98	2	NC*
Female	1.01	2	NC*	Female	3.21	4	NC*
Total	3.79	6	158	Total	6.19	6	97
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>			
Male	1.54	3	NC*	Male	47.15	45	95
Female	1.29	3	NC*				
Total	2.83	6	212				
Kidney and Re	<u>nal Pelvis</u>		St	omach_			
Male	4.87	4	NC*	Male	3.49	2	NC*
Female	3.02	3	NC*	Female	2.21	3	NC*
Total	7.89	7	89	Total	5.70	5	88
<u>Larynx</u>			$\underline{\mathbf{T}}$	<u>estis</u>			
Male	3.06	3	NC*	Male	2.33	7	300 #+
Female	0.87	0	NC*				
Total	3.93	3	NC*				
<u>Leukemia</u>				<u>hyroid</u>			
Male	3.45	5	145	Male	0.90	1	NC*
Female	2.71	2	NC*	Female	2.59	2	NC*
Total	6.16	7	114	Total	3.49	3	NC*
Liver and Intra	_			<u>teri, Corpus</u>	s and Uterus	s, NOS	
Male	1.36	0	NC*				
Female	0.63	1	NC*	Female	9.58	9	94
Total	1.99	1	NC*				
Lung and Brone		•		ll Sites / Ty		. .	
Male	26.61	31	117	Male	162.65	170	105
Female	19.33	15	78	Female	159.26	150	94
Total	45.94	46	100	Total	321.91	320	99

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

PALMER Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urinar	<u> Y</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	10.12	14	138	Male	5.03	8	159	
Female	3.78	4	NC*	Female	4.09	6	147	
Total	13.90	18	129	Total	9.13	14	153	
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>			
Male	3.34	2	NC*	Male	1.82	1	NC*	
Female	3.19	1	NC*	Female	1.69	4	NC*	
Total	6.54	3	NC*	Total	3.50	5	143	
Breast		Non-Hodgkin's Lymphoma						
Male	0.53	0	NC*	Male	7.34	5	68	
Female	58.73	57	97	Female	6.67	4	NC*	
Total	59.26	57	96	Total	14.02	9	64	
Cervix Uteri			<u>O</u> :	ral Cavity ar	<u>nd Pharynx</u>			
				Male	6.59	4	NC*	
Female	3.66	4	NC*	Female	3.01	2	NC*	
				Total	9.60	6	62	
Colon / Rectum	_		<u>O</u>	<u>vary</u>				
Male	26.92	32	119					
Female	25.35	29	114	Female	7.07	9	127	
Total	52.27	61	117					
Esophagus			<u>Pa</u>	ancreas				
Male	3.38	5	148	Male	3.70	6	162	
Female	1.26	0	NC*	Female	4.00	1	NC*	
Total	4.65	5	108	Total	7.70	7	91	

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Hodgkin's Disc	<u>Pr</u>	Prostate					
Male	1.51	1	NC*	Male	61.48	61	99
Female	1.22	1	NC*				
Total	2.73	2	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	5.80	6	103	Male	4.41	4	NC*
Female	3.54	5	141	Female	2.76	2	NC*
Total	9.34	11	118	Total	7.18	6	84
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	3.64	4	NC*	Male	2.17	1	NC*
Female	1.00	0	NC*				
Total	4.64	4	NC*				
<u>Leukemia</u>			<u>Tł</u>	<u>nyroid</u>			
Male	3.97	4	NC*	Male	0.93	1	NC*
Female	3.03	4	NC*	Female	2.54	2	NC*
Total	7.00	8	114	Total	3.47	3	NC*
Liver and Intra	ahepatic Bile	<u>Ducts</u>	<u>Uteri, Corpus and Uterus, NOS</u>				
Male	1.64	6	365 #+				
Female	0.76	0	NC*	Female	11.07	7	63
Total	2.41	6	249				
Lung and Bron	<u>chus</u>		<u>A</u> l	ll Sites / Ty	<u>pes</u>		
Male	33.09	31	94	Male	201.39	216	107
Female	23.11	27	117	Female	185.28	182	98
Total	56.20	58	103	Total	386.67	398	103

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

PAXTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u>

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Bladder, Urinar	<u>v</u>		$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>				
Male	3.47	5	144	Male	1.78	5	281		
Female	1.10	1	NC*	Female	1.39	1	NC*		
Total	4.57	6	131	Total	3.16	6	190		
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	Multiple Myeloma					
Male	1.18	0	NC*	Male	0.63	0	NC*		
Female	1.07	2	NC*	Female	0.50	0	NC*		
Total	2.25	2	NC*	Total	1.13	0	NC*		
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>1</u>			
Male	0.18	0	NC*	Male	2.54	3	NC*		
Female	19.37	24	124	Female	2.04	1	NC*		
Total	19.55	24	123	Total	4.58	4	NC*		
Cervix Uteri			<u>o</u>	ral Cavity aı	nd Pharynx				
				Male	2.42	2	NC*		
Female	1.29	4	NC*	Female	0.97	0	NC*		
				Total	3.39	2	NC*		
Colon / Rectum	_		<u>O</u>	<u>vary</u>					
Male	9.23	8	87						
Female	7.18	8	111	Female	2.38	2	NC*		
Total	16.41	16	97						
Esophagus			<u>Pa</u>	ancreas					
Male	1.22	2	NC*	Male	1.30	1	NC*		
Female	0.36	0	NC*	Female	1.16	2	NC*		
Total	1.58	2	NC*	Total	2.46	3	NC*		
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>					
Male	0.50	0	NC*	Male	21.17	20	94		
Female	0.43	0	NC*						
Total	0.93	0	NC*						
Kidney and Rei	<u>nal Pelvis</u>		St	omach_					
Male	2.08	3	NC*	Male	1.51	1	NC*		
Female	1.13	0	NC*	Female	0.77	1	NC*		
Total	3.21	3	NC*	Total	2.29	2	NC*		
<u>Larynx</u>				<u>estis</u>					
Male	1.33	1	NC*	Male	0.70	1	NC*		
Female	0.34	0	NC*						
Total	1.68	1	NC*						
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>					
Male	1.38	0	NC*	Male	0.32	0	NC*		
Female	0.95	0	NC*	Female	0.91	0	NC*		
Total	2.33	0	NC*	Total	1.23	0	NC*		
Liver and Intra	hepatic Bile l	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_			
Male	0.58	1	NC*						
Female	0.23	0	NC*	Female	3.68	5	136		
Total	0.81	1	NC*						

Lung and Bron	All Sites / Types						
Male	11.74	3	NC*	Male	70.08	57	81
Female	7.39	2	NC*	Female	58.76	57	97
Total	19.13	5	26 ^-	Total	128.84	114	88

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

PEABODY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	39.30	37	94	Male	20.23	22	109
Female	15.14	16	106	Female	16.88	13	77
Total	54.44	53	97	Total	37.11	35	94
Brain and Cen	<u>tral Nervous S</u>	<u>System</u>	Multiple Myeloma				
Male	13.35	19	142	Male	7.10	7	99
Female	12.97	10	77	Female	6.80	5	74
Total	26.32	29	110	Total	13.90	12	86
Breast			No	on-Hodgkin's	s Lymphoma	•	
Male	2.09	1	NC*	Male	28.95	28	97
Female	243.29	262	108	Female	26.86	20	74
Total	245.39	263	107	Total	55.81	48	86
Cervix Uteri			<u>O</u> :	ral Cavity an	<u>d Pharynx</u>		
				Male	27.20	26	96
Female	15.14	19	126	Female	12.39	16	129
				Total	39.59	42	106
Colon / Rectum	<u>1</u>	<u>Ovary</u>					
Male	104.59	98	94				
Female	100.65	83	82	Female	29.31	27	92
Total	205.24	181	88				

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Esophagus			<u> </u>	Pancreas Pancreas				
Male	13.68	10	73	Male	14.67	17	116	
Female	5.03	6	119	Female	15.98	24	150	
Total	18.71	16	86	Total	30.65	41	134	
Hodgkin's Dis	<u>sease</u>		<u>]</u>	<u>Prostate</u>				
Male	5.85	2	NC*	Male	238.57	218	91	
Female	4.84	3	NC*					
Total	10.69	5	47					
Kidney and R	<u>enal Pelvis</u>	al Pelvis Stomach						
Male	23.35	28	120	Male	17.20	12	70	
Female	14.40	13	90	Female	10.94	11	101	
Total	37.76	41	109	Total	28.14	23	82	
<u>Larynx</u>]	<u> </u>				
Male	14.93	18	121	Male	8.36	5	60	
Female	4.23	3	NC*					
Total	19.15	21	110					
<u>Leukemia</u>]	<u> Chyroid</u>				
Male	15.51	17	110	Male	3.74	5	134	
Female	12.03	10	83	Female	10.42	14	134	
Total	27.54	27	98	Total	14.15	19	134	
Liver and Intr	ahepatic Bil	e Ducts	<u>I</u>	<mark>Iteri, Corpu</mark>	s and Uteru	s, NOS		
Male	6.55	10	153					
Female	3.05	2	NC*	Female	46.16	60	130	
Total	9.60	12	125					
Lung and Bro	nchus_		<u> </u>	All Sites / Ty	<u>vpes</u>			
Male	131.78	142	108	Male	791.57	779	98	
Female	94.84	101	106	Female	756.26	780	103	
Total	226.62	243	107	Total	1547.83	1559	101	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

PELHAM

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\bar{\bf p}$ <= 0.001 level, as well as at the $\bar{\bf p}$ <= 0.05 and $\bar{\bf p}$ <= 0.01 levels

Cancer Incidence by Sex, 1990 - 1995 Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR		
Bladder, Urinary	_		$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>				
Male	1.09	0	NC*	Male	0.59	1	NC*		
Female	0.27	0	NC*	Female	0.41	0	NC*		
Total	1.36	0	NC*	Total	1.00	1	NC*		
Brain and Centra	al Nervous	System	$\underline{\mathbf{M}}$	<u>lultiple Myel</u>	<u>oma</u>				
Male	0.40	0	NC*	Male	0.20	0	NC*		
Female	0.30	0	NC*	Female	0.13	0	NC*		
Total	0.69	0	NC*	Total	0.33	0	NC*		
Breast			N	on-Hodgkin's	s Lymphoma	<u>1</u>			
Male	0.06	0	NC*	Male	0.84	0	NC*		
Female	5.35	2	NC*	Female	0.54	1	NC*		
Total	5.41	2	NC*	Total	1.37	1	NC*		
Cervix Uteri			Oral Cavity and Pharynx						
				Male	0.80	0	NC*		
Female	0.41	0	NC*	Female	0.26	0	NC*		
				Total	1.06	0	NC*		
Colon / Rectum			<u>O</u>	<u>vary</u>					
Male	2.90	1	NC*						
Female	1.76	1	NC*	Female	0.67	1	NC*		
Total	4.66	2	NC*						
Esophagus			<u>Pa</u>	ancreas					
Male	0.39	0	NC*	Male	0.41	1	NC*		
Female	0.09	0	NC*	Female	0.29	0	NC*		
Total	0.48	0	NC*	Total	0.70	1	NC*		
Hodgkin's Disea	<u>se</u>		<u>P</u> 1	<u>rostate</u>					
Male	0.18	0	NC*	Male	6.49	2	NC*		
Female	0.14	0	NC*						
Total	0.32	0	NC*						
Kidney and Rena	al Pelvis		<u>St</u>	<u>omach</u>					
Male	0.67	2	NC*	Male	0.48	1	NC*		
Female	0.29	0	NC*	Female	0.19	0	NC*		
Total	0.97	2	NC*	Total	0.67	1	NC*		
<u>Larynx</u>			<u>T</u>	<u>estis</u>					
Male	0.43	0	NC*	Male	0.26	0	NC*		
Female	0.09	0	NC*						
Total	0.52	0	NC*						
Leukemia			<u>T</u>	<u>hyroid</u>					
Male	0.45	0	NC*	Male	0.11	0	NC*		
Female	0.25	0	NC*	Female	0.29	0	NC*		

Total	0.70	0	NC*	Total	0.40	0	NC*		
Liver and Intrahepatic Bile Ducts			<u>U</u> 1	Uteri, Corpus and Uterus, NOS					
Male	0.19	0	NC*						
Female	0.06	0	NC*	Female	0.99	1	NC*		
Total	0.24	0	NC*						
Lung and Brone	<u>chus</u>		All Sites / Types						
Male	3.71	2	NC*	Male	22.22	10	45 ~-		
Female	1.90	1	NC*	Female	15.73	7	44 #-		
Total	5.61	3	NC*	Total	37.95	17	45 ^-		

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

PEMBROKE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR		
Bladder, Urina	<u>ry</u>	Melanoma of Skin							
Male	8.33	9	108	Male	5.06	8	158		
Female	2.88	3	NC*	Female	4.11	3	NC*		
Total	11.22	12	107	Total	9.17	11	120		
Brain and Cen	tral Nervous S	<u>System</u>	<u>M</u>	<u>ultiple Mye</u>	<u>loma</u>				
Male	3.57	6	168	Male	1.54	0	NC*		
Female	3.12	5	160	Female	1.32	1	NC*		
Total	6.69	11	164	Total	2.86	1	NC*		
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>a</u>			
Male	0.47	0	NC*	Male	7.13	8	112		
Female	54.36	59	109	Female	5.57	7	126		
Total	54.83	59	108	Total	12.70	15	118		
Cervix Uteri		Oral Cavity and Pharynx							
				Male	6.79	3	NC*		
Female	4.01	5	125	Female	2.68	2	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Total	9.46	5	53
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	22.15	24	108				
Female	18.74	20	107	Female	6.84	9	132
Total	40.90	44	108				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	3.17	8	253 #+	Male	3.25	2	NC*
Female	0.93	0	NC*	Female	3.01	2	NC*
Total	4.09	8	195	Total	6.26	4	NC*
Hodgkin's Dis	<u>ease</u>		<u>Pr</u>	<u>rostate</u>			
Male	1.80	4	NC*	Male	48.11	48	100
Female	1.42	1	NC*				
Total	3.21	5	156				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	5.53	5	90	Male	3.73	7	188
Female	3.04	2	NC*	Female	2.06	0	NC*
Total	8.58	7	82	Total	5.79	7	121
<u>Larynx</u>				<u>estis</u>			
Male	3.53	2	NC*	Male	2.75	3	NC*
Female	0.93	0	NC*				
Total	4.46	2	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>hyroid</u>			
Male	3.84	5	130	Male	1.08	0	NC*
Female	2.78	1	NC*	Female	2.89	1	NC*
Total	6.62	6	91	Total	3.97	1	NC*
Liver and Intra	_	<u>Ducts</u>		<u>teri, Corpus</u>	and Uterus,	NOS	
Male	1.51	1	NC*				
Female	0.61	1	NC*	Female	10.07	14	139
Total	2.12	2	NC*				
Lung and Bron				ll Sites / Ty			
Male	29.08	36	124	Male	175.41	192	109
Female	19.32	31	160 #+	Female	162.02	175	108
Total	48.41	67	138 #+	Total	337.43	367	109

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

PEPPERELL

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>			
Male	4.84	5	103	Male	3.12	2	NC*	
Female	1.89	4	NC*	Female	2.73	1	NC*	
Total	6.72	9	134	Total	5.85	3	NC*	
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	2.31	5	217	Male	0.90	0	NC*	
Female	2.06	4	NC*	Female	0.85	2	NC*	
Total	4.37	9	206	Total	1.75	2	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>		
Male	0.28	2	NC*	Male	4.47	2	NC*	
Female	34.59	33	95	Female	3.68	5	136	
Total	34.87	35	100	Total	8.15	7	86	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	4.03	5	124	
Female	2.75	5	182	Female	1.70	3	NC*	
				Total	5.73	8	140	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	12.86	10	78					
Female	12.41	5	40 #-	Female	4.40	5	114	
Total	25.27	15	59 #-					
Esophagus			<u>Pa</u>	ancreas				
Male	1.84	2	NC*	Male	1.90	2	NC*	
Female	0.61	1	NC*	Female	1.96	2	NC*	
Total	2.44	3	NC*	Total	3.86	4	NC*	
Hodgkin's Disc	ease_		<u>P</u> 1	<u>rostate</u>				
Male	1.29	1	NC*	Male	27.57	26	94	
Female	1.04	1	NC*					
Total	2.32	2	NC*					
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>				
Male	3.29	4	NC*	Male	2.18	0	NC*	
Female	1.95	1	NC*	Female	1.38	0	NC*	
Total	5.24	5	95	Total	3.56	0	NC*	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	2.05	3	NC*	Male	2.04	4	NC*	

Female	0.56	1	NC*					
Total	2.61	4	NC*					
Leukemia			<u>Tł</u>	<u>nyroid</u>				
Male	2.43	2	NC*	Male	0.72	0	NC*	
Female	1.88	1	NC*	Female	2.02	2	NC*	
Total	4.31	3	NC*	Total	2.74	2	NC*	
Liver and Intr	ahepatic Bile I	<u> Ducts</u>	<u>Uteri, Corpus and Uterus, NOS</u>					
Male	0.90	0	NC*					
Female	0.40	1	NC*	Female	6.23	2	NC*	
Total	1.30	1	NC*					
Lung and Bron	<u>ichus</u>		<u>A</u> l	ll Sites / Ty	pes			
Male	16.85	15	89	Male	103.91	97	93	
Female	12.08	13	108	Female	104.67	100	96	
Total	28.94	28	97	Total	208.59	197	94	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

PERU

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>v</u>	Melanoma of Skin							
Male	0.46	0	NC*	Male	0.26	0	NC*		
Female	0.12	1	NC*	Female	0.18	0	NC*		
Total	0.58	1	NC*	Total	0.44	0	NC*		
Brain and Cent	ral Nervous S	<u>system</u>	<u>oma</u>						
Male	0.18	0	NC*	Male	0.09	0	NC*		
Female	0.14	0	NC*	Female	0.06	0	NC*		
Total	0.33	0	NC*	Total	0.14	0	NC*		
Breast		Non-Hodgkin's Lymphoma							
Male	0.03	0	NC*	Male	0.37	0	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	2.27	1	NC*	Female	0.24	0	NC*
Total	2.30	1	NC*	Total	0.61	0	NC*
Cervix Uteri			<u>O</u> :	ral Cavity ar	nd Pharynx		
				Male	0.34	0	NC*
Female	0.18	1	NC*	Female	0.11	0	NC*
				Total	0.45	0	NC*
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	1.23	1	NC*				
Female	0.78	0	NC*	Female	0.29	0	NC*
Total	2.02	1	NC*				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	0.16	0	NC*	Male	0.17	0	NC*
Female	0.04	0	NC*	Female	0.13	0	NC*
Total	0.20	0	NC*	Total	0.30	0	NC*
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>			
Male	0.09	0	NC*	Male	2.71	0	NC*
Female	0.07	0	NC*				
Total	0.16	0	NC*				
Kidney and Re	<u>nal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	0.29	0	NC*	Male	0.20	0	NC*
Female	0.13	0	NC*	Female	0.08	0	NC*
Total	0.42	0	NC*	Total	0.29	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.18	0	NC*	Male	0.13	0	NC*
Female	0.04	0	NC*				
Total	0.22	0	NC*				
Leukemia			<u>Tl</u>	<u>hyroid</u>			
Male	0.21	0	NC*	Male	0.05	0	NC*
Female	0.13	1	NC*	Female	0.13	0	NC*
Total	0.33	1	NC*	Total	0.19	0	NC*
Liver and Intra	hepatic Bile D	<u>Oucts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.08	0	NC*				
Female	0.03	0	NC*	Female	0.42	0	NC*
Total	0.11	0	NC*				
Lung and Brone	<u>chus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>		
Male	1.56	0	NC*	Male	9.50	1	NC*
Female	0.84	1	NC*	Female	6.90	6	87
Total	2.40	1	NC*	Total	16.41	7	43 #-

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

PETERSHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>v</u>		<u>M</u>	<u>lelanoma of S</u>	<u>Skin</u>				
Male	1.06	1	NC*	Male	0.54	0	NC*		
Female	0.44	1	NC*	Female	0.45	1	NC*		
Total	1.50	2	NC*	Total	0.99	1	NC*		
Brain and Central Nervous System M				<u>lultiple Myel</u>	<u>oma</u>				
Male	0.35	0	NC*	Male	0.19	0	NC*		
Female	0.34	0	NC*	Female	0.20	0	NC*		
Total	0.70	0	NC*	Total	0.39	0	NC*		
Breast			<u>N</u>	on-Hodgkin's	<u>Lymphoma</u>	<u>1</u>			
Male	0.06	0	NC*	Male	0.77	0	NC*		
Female	6.60	5	76	Female	0.76	0	NC*		
Total	6.66	5	75	Total	1.53	0	NC*		
Cervix Uteri			Oral Cavity and Pharynx						
				Male	0.73	0	NC*		
Female	0.39	0	NC*	Female	0.34	0	NC*		
				Total	1.08	0	NC*		
Colon / Rectum			<u>O</u>	<u>vary</u>					
Male	2.81	2	NC*						
Female	2.99	1	NC*	Female	0.78	0	NC*		
Total	5.80	3	NC*						
Esophagus			<u>Pa</u>	ancreas					
Male	0.37	1	NC*	Male	0.39	0	NC*		
Female	0.15	0	NC*	Female	0.46	1	NC*		
Total	0.52	1	NC*	Total	0.86	1	NC*		
Hodgkin's Dise	ase_		<u>P1</u>	<u>rostate</u>					
Male	0.15	0	NC*	Male	6.37	7	110		
Female	0.12	0	NC*						
Total	0.27	0	NC*						
Kidney and Ren	nal Pelvis		<u>St</u>	<u>omach</u>					
Male	0.63	2	NC*	Male	0.46	0	NC*		

Female	0.39	0	NC*	Female	0.33	0	NC*
Total	1.02	2	NC*	Total	0.79	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.40	0	NC*	Male	0.21	0	NC*
Female	0.11	0	NC*				
Total	0.52	0	NC*				
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>			
Male	0.41	0	NC*	Male	0.10	0	NC*
Female	0.33	0	NC*	Female	0.26	0	NC*
Total	0.75	0	NC*	Total	0.36	0	NC*
Liver and Intra	<u>ahepatic Bile D</u>	<u>ucts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.18	0	NC*				
Female	0.09	0	NC*	Female	1.24	1	NC*
Total	0.26	0	NC*				
Lung and Bron	<u>ichus</u>		$\underline{\mathbf{A}}$	ll Sites / Typ	<u>oes</u>		
Male	3.53	2	NC*	Male	21.17	16	76
Female	2.57	1	NC*	Female	20.93	14	67
Total	6.10	3	NC*	Total	42.10	30	71

SIR = standardized incidence ratio [(Obs / Exp) X 100]

PHILLIPSTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>v</u>	Melanoma of Skin							
Male	0.95	1	NC*	Male	0.57	0	NC*		
Female	0.25	0	NC*	Female	0.38	4	NC*		
Total	1.20	1	NC*	Total	0.95	4	NC*		
Brain and Cent	al Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>				
Male	0.40	1	NC*	Male	0.18	0	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	0.29	0	NC*	Female	0.12	0	NC*
Total	0.69	1	NC*	Total	0.29	0	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>L</u>	
Male	0.05	0	NC*	Male	0.81	0	NC*
Female	4.95	2	NC*	Female	0.50	0	NC*
Total	5.00	2	NC*	Total	1.31	0	NC*
Cervix Uteri			<u>o</u>	ral Cavity aı	nd Pharynx		
				Male	0.75	4	NC*
Female	0.38	1	NC*	Female	0.24	0	NC*
				Total	0.99	4	NC*
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	2.53	2	NC*				
Female	1.61	0	NC*	Female	0.63	0	NC*
Total	4.14	2	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.35	1	NC*	Male	0.36	0	NC*
Female	0.08	0	NC*	Female	0.26	2	NC*
Total	0.43	1	NC*	Total	0.63	2	NC*
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>			
Male	0.20	0	NC*	Male	5.44	7	129
Female	0.14	1	NC*				
Total	0.34	1	NC*				
Kidney and Rei	nal Pelvis		St	omach_			
Male	0.62	0	NC*	Male	0.43	0	NC*
Female	0.28	0	NC*	Female	0.17	0	NC*
Total	0.90	0	NC*	Total	0.60	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.39	1	NC*	Male	0.32	1	NC*
Female	0.09	0	NC*				
Total	0.47	1	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	0.43	0	NC*	Male	0.12	0	NC*
Female	0.26	1	NC*	Female	0.27	0	NC*
Total	0.69	1	NC*	Total	0.40	0	NC*
Liver and Intra	hepatic Bile I	<u> Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	0.17	0	NC*				
Female	0.06	0	NC*	Female	0.92	1	NC*
Total	0.22	0	NC*				
Lung and Brono	<u>chus</u>		<u>A</u>	ll Sites / Typ	<u>oes</u>		
Male	3.25	0	NC*	Male	19.78	19	96
Female	1.77	3	NC*	Female	14.66	17	116
Total	5.02	3	NC*	Total	34.44	36	105

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

PITTSFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	$\underline{\mathbf{Exp}}$	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>			
Male	41.48	47	113	Male	20.26	11	54 #-	
Female	16.84	16	95	Female	17.36	15	86	
Total	58.32	63	108	Total	37.62	26	69	
Brain and Cen	tral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	<u> [ultiple Myel</u>	<u>oma</u>			
Male	13.27	11	83	Male	7.44	6	81	
Female	13.53	13	96	Female	7.47	5	67	
Total	26.81	24	90	Total	14.91	11	74	
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	ı		
Male	2.17	2	NC*	Male	29.45	26	88	
Female	253.89	232	91	Female	29.23	15	51 ~-	
Total	256.06	234	91	Total	58.68	41	70 #-	
<u>Cervix Uteri</u>			Oral Cavity and Pharynx					
				Male	26.65	19	71	
Female	15.17	12	79	Female	13.07	10	76	
				Total	39.72	29	73	
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	110.08	116	105					
Female	113.40	100	88	Female	30.27	23	76	
Total	223.49	216	97					
Esophagus			<u>Pa</u>	ancreas				
Male	13.78	13	94	Male	15.03	13	87	
Female	5.65	5	89	Female	17.80	22	124	
Total	19.42	18	93	Total	32.83	35	107	
Hodgkin's Dis	ease		<u>P</u> 1	<u>rostate</u>				

Male	5.79	10	173	Male	249.08	136	55 ^-		
Female	4.92	0	NC*						
Total	10.72	10	93						
Kidney and Re	enal Pelvis		St	<u>omach</u>					
Male	23.42	21	90	Male	18.11	13	72		
Female	15.39	9	58	Female	12.38	12	97		
Total	38.81	30	77	Total	30.49	25	82		
<u>Larynx</u>			<u>T</u>	<u>estis</u>					
Male	14.73	10	68	Male	8.13	8	98		
Female	4.33	2	NC*						
Total	19.06	12	63						
Leukemia			<u>Tl</u>	<u>hyroid</u>					
Male	15.96	15	94	Male	3.63	3	NC*		
Female	13.02	11	84	Female	10.41	11	106		
Total	28.98	26	90	Total	14.05	14	100		
Liver and Intra	ahepatic Bile	<u>Ducts</u>	<u>U</u> 1	Uteri, Corpus and Uterus, NOS					
Male	6.65	9	135						
Female	3.35	2	NC*	Female	47.98	43	90		
Total	10.00	11	110						
Lung and Bron	<u>ichus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>				
Male	133.91	106	79 #-	Male	815.38	632	78 ^-		
Female	101.00	67	66 ^-	Female	806.69	677	84 ^-		
Total	234.91	173	74 ^-	Total	1622.07	1309	81 ^-		

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

PLAINFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

Exp Obs SIR Exp Obs SIR

Bladder, Urinary Melanoma of Skin

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	0.48	1	NC*	Male	0.25	0	NC*
Female	0.12	0	NC*	Female	0.17	0	NC*
Total	0.60	1	NC*	Total	0.42	0	NC*
Brain and Cent	ral Nervous S	<u>vstem</u>	<u>M</u>	ultiple Myel	<u>oma</u>		
Male	0.16	0	NC*	Male	0.09	0	NC*
Female	0.13	0	NC*	Female	0.06	0	NC*
Total	0.29	0	NC*	Total	0.14	0	NC*
Breast			<u>N</u>	on-Hodgkin's	s Lymphoma	<u> </u>	
Male	0.03	0	NC*	Male	0.35	1	NC*
Female	2.32	2	NC*	Female	0.23	0	NC*
Total	2.35	2	NC*	Total	0.58	1	NC*
Cervix Uteri			<u>O</u>	ral Cavity an	d Pharynx		
				Male	0.34	0	NC*
Female	0.16	0	NC*	Female	0.11	0	NC*
				Total	0.45	0	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	1.28	0	NC*				
Female	0.76	0	NC*	Female	0.29	1	NC*
Total	2.04	0	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.17	0	NC*	Male	0.18	0	NC*
Female	0.04	0	NC*	Female	0.13	0	NC*
Total	0.21	0	NC*	Total	0.31	0	NC*
Hodgkin's Dise	<u>ase</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.07	0	NC*	Male	2.92	0	NC*
Female	0.05	0	NC*				
Total	0.12	0	NC*				
Kidney and Ren	nal Pelvis		St	<u>omach</u>			
Male	0.29	0	NC*	Male	0.21	0	NC*
Female	0.13	0	NC*	Female	0.08	0	NC*
Total	0.42	0	NC*	Total	0.29	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.19	0	NC*	Male	0.10	1	NC*
Female	0.04	0	NC*				
Total	0.23	0	NC*				
Leukemia			<u>T</u>]	<u>nyroid</u>			
Male	0.19	0	NC*	Male	0.05	0	NC*
Female	0.11	0	NC*	Female	0.11	1	NC*
Total	0.30	0	NC*	Total	0.16	1	NC*
Liver and Intra	hepatic Bile L	<u> Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	0.08	0	NC*				
Female	0.03	0	NC*	Female	0.44	2	NC*
Total	0.11	0	NC*				
Lung and Brond	<u>chus</u>		<u>A</u>]	ll Sites / Typ	<u>es</u>		

Male	1.63	0	NC*	Male	9.70	3	NC*
Female	0.86	0	NC*	Female	6.83	6	88
Total	2.49	0	NC*	Total	16.53	9	54

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

PLAINVILLE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary	-		$\underline{\mathbf{M}}$	<u>lelanoma of </u>	<u>Skin</u>		
Male	5.23	5	96	Male	2.87	6	209
Female	1.94	0	NC*	Female	2.38	3	NC*
Total	7.17	5	70	Total	5.26	9	171
Brain and Centra	al Nervous	<u>System</u>	$\underline{\mathbf{M}}$	<u>[ultiple Mye</u>]	<u>loma</u>		
Male	1.95	4	NC*	Male	0.95	0	NC*
Female	1.80	0	NC*	Female	0.87	2	NC*
Total	3.75	4	NC*	Total	1.83	2	NC*
Breast	Non-Hodgkin's Lymphoma						
Male	0.28	1	NC*	Male	4.15	3	NC*
Female	32.81	32	98	Female	3.56	4	NC*
Total	33.09	33	100	Total	7.71	7	91
Cervix Uteri			<u>O</u>	ral Cavity ar	nd Pharynx		
				Male	3.75	1	NC*
Female	2.25	0	NC*	Female	1.65	1	NC*
				Total	5.39	2	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	13.91	7	50				
Female	12.84	5	39 #-	Female	4.02	4	NC*
Total	26.75	12	45 ~-				
Esophagus			<u>Pa</u>	ancreas			

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	1.83	1	NC*	Male	1.96	1	NC*		
Female	0.64	0	NC*	Female	2.05	0	NC*		
Total	2.47	1	NC*	Total	4.01	1	NC*		
Hodgkin's Dis	<u>ease</u>	<u>Prostate</u>							
Male	0.97	0	NC*	Male	31.07	23	74		
Female	0.76	3	NC*						
Total	1.73	3	NC*						
Kidney and Re	Kidney and Renal Pelvis Stomach								
Male	3.19	3	NC*	Male	2.31	2	NC*		
Female	1.90	2	NC*	Female	1.40	0	NC*		
Total	5.09	5	98	Total	3.70	2	NC*		
<u>Larynx</u>			<u>T</u>	<u>estis</u>					
Male	2.00	2	NC*	Male	1.50	1	NC*		
Female	0.56	1	NC*						
Total	2.56	3	NC*						
Leukemia			<u>Tl</u>	<u>nyroid</u>					
Male	2.19	1	NC*	Male	0.59	0	NC*		
Female	1.64	1	NC*	Female	1.58	1	NC*		
Total	3.83	2	NC*	Total	2.17	1	NC*		
Liver and Intra	<u>ahepatic Bile l</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus.	NOS			
Male	0.89	2	NC*						
Female	0.40	1	NC*	Female	6.13	6	98		
Total	1.29	3	NC*						
Lung and Bron	<u>ichus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>				
Male	17.52	15	86	Male	106.78	87	81		
Female	12.41	7	56	Female	100.80	80	79 #-		
Total	29.93	22	73	Total	207.59	167	80 ~-		

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

PLYMOUTH

Cancer Incidence by Sex, 1990 - 1995

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	31.19	54	173 ^+	Male	17.03	16	94
Female	11.92	17	143	Female	14.08	22	156
Total	43.11	71	165 ^+	Total	31.11	38	122
Brain and Cen	tral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	11.78	15	127	Male	5.67	6	106
Female	10.81	13	120	Female	5.29	3	NC*
Total	22.59	28	124	Total	10.95	9	82
Breast			N	<u>on-Hodgkin'</u>	's Lymphoma	_	
Male	1.69	0	NC*	Male	24.62	27	110
Female	192.54	178	92	Female	21.58	25	116
Total	194.23	178	92	Total	46.20	52	113
Cervix Uteri			<u>O</u>	ral Cavity aı	<u>nd Pharynx</u>		
				Male	22.17	23	104
Female	13.12	14	107	Female	9.75	15	154
				Total	31.92	38	119
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	82.78	77	93				
Female	79.76	68	85	Female	23.62	14	59 #-
Total	162.54	145	89				
Esophagus			<u>Pa</u>	ancreas_			
Male	10.87	7	64	Male	11.60	6	52
Female	3.93	1	NC*	Female	12.47	14	112
Total	14.81	8	54	Total	24.08	20	83
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	5.83	9	154	Male	182.78	204	112
Female	4.63	2	NC*				
Total	10.47	11	105				
Kidney and Re	enal Pelvis		<u>St</u>	omach_			
Male	18.88	18	95	Male	13.80	10	72
Female	11.30	11	97	Female	8.81	6	68
Total	30.18	29	96	Total	22.61	16	71
<u>Larynx</u>			$\underline{\mathbf{T}}$	<u>estis</u>			
Male	11.81	18	152	Male	8.78	7	80
Female	3.18	3	NC*				
Total	14.99	21	140				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	13.36	17	127	Male	3.45	1	NC*
Female	10.28	12	117	Female	9.35	4	NC*
Total	23.64	29	123	Total	12.80	5	39 #-

Liver and Intrahepatic Bile Ducts			<u>U</u> 1	<u>Uteri, Corpus and Uterus, NOS</u>					
Male	5.27	5	95						
Female	2.42	1	NC*	Female	35.50	36	101		
Total	7.70	6	78						
Lung and Bron	<u>ichus</u>	<u>is</u>			All Sites / Types				
Male	103.14	101	98	Male	632.43	665	105		
Female	71.91	76	106	Female	600.80	579	96		
Total	175.05	177	101	Total	1233.23	1244	101		

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

PLYMPTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary	<u>-</u>		<u>M</u>	elanoma of	<u>Skin</u>		
Male	1.42	1	NC*	Male	0.89	1	NC*
Female	0.42	0	NC*	Female	0.67	1	NC*
Total	1.84	1	NC*	Total	1.55	2	NC*
Brain and Centr	al Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>loma</u>		
Male	0.63	0	NC*	Male	0.26	0	NC*
Female	0.51	0	NC*	Female	0.20	0	NC*
Total	1.13	0	NC*	Total	0.46	0	NC*
Breast			No	on-Hodgkin'	s Lymphoma	<u>a</u>	
Male	0.08	0	NC*	Male	1.24	1	NC*
Female	8.72	5	57	Female	0.85	2	NC*
Total	8.80	5	57	Total	2.09	3	NC*
Cervix Uteri			<u>O</u> 1	ral Cavity ar	nd Pharynx		
				Male	1.20	0	NC*
Female	0.66	0	NC*	Female	0.42	2	NC*
				Total	1.62	2	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Colon / Rectur	<u>n</u>		<u>O</u>	<u>vary</u>			
Male	3.76	6	159				
Female	2.71	5	185	Female	1.11	1	NC*
Total	6.47	11	170				
Esophagus			<u>Pa</u>	ncreas			
Male	0.55	0	NC*	Male	0.56	0	NC*
Female	0.13	0	NC*	Female	0.45	0	NC*
Total	0.69	0	NC*	Total	1.00	0	NC*
Hodgkin's Dis	<u>sease</u>		<u>Pr</u>	<u>ostate</u>			
Male	0.32	0	NC*	Male	8.07	8	99
Female	0.24	0	NC*				
Total	0.55	0	NC*				
Kidney and R	<u>enal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	0.96	3	NC*	Male	0.64	0	NC*
Female	0.48	0	NC*	Female	0.29	0	NC*
Total	1.44	3	NC*	Total	0.93	0	NC*
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	0.62	0	NC*	Male	0.49	0	NC*
Female	0.15	0	NC*				
Total	0.77	0	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>ıyroid</u>			
Male	0.66	1	NC*	Male	0.19	0	NC*
Female	0.43	0	NC*	Female	0.48	0	NC*
Total	1.10	1	NC*	Total	0.67	0	NC*
Liver and Intr	<u>ahepatic Bile l</u>	<u>Ducts</u>		t <mark>eri, Corpus</mark>	and Uterus,	NOS_	
Male	0.26	0	NC*				
Female	0.09	0	NC*	Female	1.63	0	NC*
Total	0.35	0	NC*				
Lung and Bro	<u>nchus</u>		<u>A</u> l	l Sites / Typ	<u>oes</u>		
Male	4.99	3	NC*	Male	30.03	27	90
Female	3.08	1	NC*	Female	25.45	17	67
Total	8.07	4	NC*	Total	55.48	44	79

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

PRINCETON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>v</u>		<u>M</u>	lelanoma of	<u>Skin</u>		
Male	1.95	5	256	Male	1.14	0	NC*
Female	0.56	1	NC*	Female	0.86	2	NC*
Total	2.51	6	239	Total	2.00	2	NC*
Brain and Cent	<u>ral Nervous S</u>	<u>System</u>	$\underline{\mathbf{M}}$	<u>[ultiple Mye</u>	<u>loma</u>		
Male	0.80	2	NC*	Male	0.36	0	NC*
Female	0.65	1	NC*	Female	0.26	0	NC*
Total	1.45	3	NC*	Total	0.62	0	NC*
Breast			<u>N</u>	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>	
Male	0.11	0	NC*	Male	1.60	2	NC*
Female	11.24	11	98	Female	1.12	0	NC*
Total	11.35	11	97	Total	2.72	2	NC*
<u>Cervix Uteri</u>			<u>O</u> :	<u>ral Cavity ar</u>	<u>nd Pharynx</u>		
				Male	1.57	0	NC*
Female	0.85	1	NC*	Female	0.54	1	NC*
				Total	2.11	1	NC*
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	5.19	4	NC*				
Female	3.60	6	167	Female	1.43	1	NC*
Total	8.79	10	114				
Esophagus			<u>Pa</u>	ancreas			
Male	0.74	0	NC*	Male	0.76	1	NC*
Female	0.18	0	NC*	Female	0.59	0	NC*
Total	0.92	0	NC*	Total	1.35	1	NC*
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>			
Male	0.38	0	NC*	Male	11.32	8	71
Female	0.30	0	NC*				
Total	0.68	0	NC*				
Kidney and Re	<u>nal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	1.29	0	NC*	Male	0.87	0	NC*
Female	0.62	1	NC*	Female	0.39	0	NC*
Total	1.91	1	NC*	Total	1.26	0	NC*
<u>Larynx</u>				<u>estis</u>			
Male	0.83	0	NC*	Male	0.54	3	NC*
Female	0.19	0	NC*				

Total	1.02	0	NC*					
Leukemia			<u>Tl</u>	<u>nyroid</u>				
Male	0.88	3	NC*	Male	0.23	0	NC*	
Female	0.56	0	NC*	Female	0.62	0	NC*	
Total	1.44	3	NC*	Total	0.85	0	NC*	
Liver and Intrahepatic Bile Ducts			<u>U</u> 1	<u>Uteri, Corpus and Uterus, NOS</u>				
Male	0.35	1	NC*					
Female	0.12	1	NC*	Female	2.09	2	NC*	
Total	0.47	2	NC*					
Lung and Bron	<u>chus</u>		<u>A</u>]	All Sites / Types				
Male	6.83	9	132	Male	40.68	38	93	
Female	3.98	4	NC*	Female	33.02	36	109	
Total	10.81	13	120	Total	73.70	74	100	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

PROVINCETOWN

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>			
Bladder, Urina	<u>ry</u>		Melanoma of Skin							
Male	3.50	5	143	Male	1.74	1	NC*			
Female	1.34	3	NC*	Female	1.36	2	NC*			
Total	4.85	8	165	Total	3.10	3	NC*			
Brain and Central Nervous System Multiple				ultiple Mye	<u>loma</u>					
Male	1.09	1	NC*	Male	0.63	1	NC*			
Female	1.01	4	NC*	Female	0.59	2	NC*			
Total	2.09	5	239	Total	1.22	3	NC*			
Breast			Non-Hodgkin's Lymphoma							
Male	0.19	0	NC*	Male	2.48	11	443 ^+			
Female	19.85	14	71	Female	2.29	4	NC*			

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	20.03	14	70	Total	4.77	15	315 ^+
<u>Cervix Uteri</u>			<u>O</u> :	-	nd Pharynx	_	214
г 1	1 17	~	406 11.	Male	2.33	5	214
Female	1.17	5	426 #+	Female	1.02	0	NC*
C-1 / D4	_		0	Total	3.35	5	149
Colon / Rectun		6		<u>vary</u>			
Male	9.29	6	65	П 1	2.25	2	MOW
Female	9.11	8	88	Female	2.35	3	NC*
Total	18.40	14	76 P				
Esophagus	4.40	0		ancreas_	1.00		3.7.O.I.
Male	1.19	0	NC*	Male	1.28	2	NC*
Female	0.45	0	NC*	Female	1.40	2	NC*
Total	1.64	0	NC*	Total	2.68	4	NC*
Hodgkin's Dis			_	<u>rostate</u>			
Male	0.45	1	NC*	Male	20.77	26	125
Female	0.35	0	NC*				
Total	0.81	1	NC*				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	2.00	1	NC*	Male	1.53	0	NC*
Female	1.16	2	NC*	Female	1.02	2	NC*
Total	3.16	3	NC*	Total	2.55	2	NC*
<u>Larynx</u>			<u>T</u>	estis_			
Male	1.28	1	NC*	Male	0.65	1	NC*
Female	0.33	1	NC*				
Total	1.61	2	NC*				
Leukemia			<u>T</u>	nyroid			
Male	1.29	1	NC*	Male	0.31	0	NC*
Female	0.99	1	NC*	Female	0.80	1	NC*
Total	2.28	2	NC*	Total	1.10	1	NC*
Liver and Intra	ahepatic Bile	Ducts	<u>U</u> 1	teri, Corpus	and Uterus	, NOS	
Male	0.56	0	NC*				
Female	0.26	0	NC*	Female	3.68	3	NC*
Total	0.82	0	NC*				
Lung and Bron				ll Sites / Ty	pes		
Male	11.40	12	105	Male	68.67	98	143 ~+
Female	7.54	12	159	Female	62.84	74	118
Total	18.95	24	127	Total	131.51	172	131 ^+
10111	10.75	2 1	121	101111	101.01	1,2	101

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

QUINCY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	66.86	58	87	Male	34.29	34	99	
Female	29.00	37	128	Female	31.47	33	105	
Total	95.86	95	99	Total	65.77	67	102	
Brain and Cen	tral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	Multiple Myeloma				
Male	22.41	33	147 #+	Male	12.03	9	75	
Female	23.71	26	110	Female	12.82	17	133	
Total	46.12	59	128	Total	24.85	26	105	
Breast				on-Hodgkin	<u>'s Lymphoma</u>	-		
Male	3.54	4	NC*	Male	49.74	49	99	
Female	445.18	433	97	Female	51.03	46	90	
Total	448.71	437	97	Total	100.78	95	94	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	44.37	76	171 ^+	
Female	28.52	31	109	Female	22.70	25	110	
				Total	67.07	101	151 ^+	
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	177.35	185	104					
Female	195.45	200	102	Female	53.54	42	78	
Total	372.80	385	103					
Esophagus			<u>Pa</u>	<u>ancreas</u>				
Male	22.43	29	129	Male	24.38	32	131	
Female	9.68	7	72	Female	30.54	19	62 #-	
Total	32.10	36	112	Total	54.92	51	93	
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	10.61	10	94	Male	395.95	453	114 ~+	
Female	9.44	7	74					
Total	20.05	17	85					
Kidney and Re	enal Pelvis		<u>St</u>	tomach_				
Male	38.38	43	112	Male	29.39	30	102	
Female	26.45	30	113	Female	21.47	26	121	

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	64.84	73	113	Total	50.86	56	110
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	24.06	27	112	Male	16.20	16	99
Female	7.39	12	162				
Total	31.45	39	124				
Leukemia			<u>T</u>	<u>iyroid</u>			
Male	26.11	27	103	Male	6.57	4	NC*
Female	22.65	26	115	Female	19.83	24	121
Total	48.76	53	109	Total	26.40	28	106
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri, Corpus and Intrahepatic Bile Ducts</u>					and Uterus,	NOS	
Male	10.85	15	138				
Female	5.75	6	104	Female	82.80	72	87
Total	16.60	21	126				
Lung and Bro	nchus		<u>A</u> l	l Sites / Ty	pes		
Male	216.11	247	114 #+	Male	1324.95	1492	113 ^+
Female	172.38	214	124 ~+	Female	1406.50	1421	101
Total	388.49	461	119 ^+	Total	2731.45	2913	107 ^+

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

RANDOLPH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urin	<u>ary</u>		Melanoma of Skin						
Male	24.55	17	69	Male	12.63	17	135		
Female	9.65	8	83	Female	10.72	13	121		
Total	34.20	25	73	Total	23.35	30	128		
Brain and Ce	ntral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$						
Male	8.35	6	72	Male	4.43	4	NC*		
Female	8.14	7	86	Female	4.29	2	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	16.50	13	79	Total	8.72	6	69
Breast			No	on-Hodgkin	's Lymphon	<u>na</u>	
Male	1.31	1	NC*	Male	18.17	18	99
Female	152.53	149	98	Female	17.07	9	53
Total	153.84	150	98	Total	35.24	27	77
<u>Cervix Uteri</u>			<u>O</u> :	<u>ral Cavity a</u>	<u>nd Pharynx</u>	-	
				Male	16.75	23	137
Female	9.65	12	124	Female	7.75	7	90
				Total	24.50	30	122
Colon / Rectun				<u>vary</u>			
Male	65.18	61	94				
Female	64.66	73	113	Female	18.39	24	130
Total	129.84	134	103				
Esophagus				<u>ancreas</u>			
Male	8.43	8	95	Male	9.06	13	143
Female	3.20	3	NC*	Female	10.14	8	79
Total	11.63	11	95	Total	19.21	21	109
Hodgkin's Dis	<u>sease</u>		<u>Pr</u>	<u>costate</u>			
Male	3.77	4	NC*	Male	146.66	173	118 #+
Female	3.14	5	159				
Total	6.92	9	130				
Kidney and Ro	<u>enal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	14.40	15	104	Male	10.77	17	158
Female	8.98	7	78	Female	7.11	4	NC*
Total	23.37	22	94	Total	17.88	21	117
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	9.13	12	131	Male	5.49	6	109
Female	2.58	2	NC*				
Total	11.71	14	120				
<u>Leukemia</u>				<u>iyroid</u>			
Male	9.73	7	72	Male	2.37	2	NC*
Female	7.70	10	130	Female	6.70	8	119
Total	17.43	17	98	Total	9.06	10	110
Liver and Intr	<u>-</u>		· · · · · · · · · · · · · · · · · · ·	t <mark>eri, Corpus</mark>	and Uterus	s, NOS	
Male	4.05	6	148				
Female	1.92	4	NC*	Female	28.55	25	88
Total	5.97	10	167				
Lung and Broi			·	ll Sites / Ty			
Male	80.89	87	108	Male	490.34	527	107
Female	58.43	67	115	Female	476.44	488	102
Total	139.31	154	111	Total	966.78	1015	105

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

RAYNHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinaı	<u>ry</u>		<u>M</u>	lelanoma of	<u>Skin</u>				
Male	7.63	6	79	Male	4.05	3	NC*		
Female	2.61	1	NC*	Female	3.20	2	NC*		
Total	10.24	7	68	Total	7.26	5	69		
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>				
Male	2.76	0	NC*	Male	1.39	2	NC*		
Female	2.48	0	NC*	Female	1.19	3	NC*		
Total	5.24	0	NC*	Total	2.58	5	194		
Breast			No	on-Hodgkin'	s Lymphoma	<u>ı</u>			
Male	0.41	0	NC*	Male	5.79	7	121		
Female	45.05	47	104	Female	4.79	5	104		
Total	45.46	47	103	Total	10.59	12	113		
<u>Cervix Uteri</u>			Oral Cavity and Pharynx						
				Male	5.48	3	NC*		
Female	2.96	2	NC*	Female	2.26	3	NC*		
				Total	7.74	6	78		
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>					
Male	20.34	23	113						
Female	17.14	19	111	Female	5.52	5	91		
Total	37.48	42	112						
Esophagus			<u>Pa</u>	ancreas					
Male	2.72	2	NC*	Male	2.88	2	NC*		
Female	0.86	2	NC*	Female	2.76	2	NC*		
Total	3.57	4	NC*	Total	5.64	4	NC*		
Hodgkin's Dise	<u>ease</u>		<u>P</u> 1	<u>rostate</u>					
Male	1.24	1	NC*	Male	46.16	59	128		

Female	0.99	3	NC*				
Total	2.23	4	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	4.67	7	150	Male	3.35	3	NC*
Female	2.63	2	NC*	Female	1.85	1	NC*
Total	7.30	9	123	Total	5.20	4	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.98	0	NC*	Male	1.75	1	NC*
Female	0.79	1	NC*				
Total	3.77	1	NC*				
Leukemia			<u>Tl</u>	<u>hyroid</u>			
Male	3.17	4	NC*	Male	0.77	0	NC*
Female	2.24	2	NC*	Female	2.08	2	NC*
Total	5.41	6	111	Total	2.85	2	NC*
Liver and Intra	hepatic Bile I	<u> Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
Male	1.30	1	NC*				
Female	0.54	0	NC*	Female	8.54	2	NC*
Total	1.84	1	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty	pes		
Male	25.97	27	104	Male	155.72	153	98
Female	17.22	17	99	Female	137.41	125	91
Total	43.19	44	102	Total	293.13	278	95

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

READING

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>v</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	17.02	22	129	Male	9.01	11	122

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	6.43	3	NC*	Female	7.50	6	80
Total	23.45	25	107	Total	16.50	17	103
Brain and Cent	tral Nervous	<u>System</u>	<u>M</u>	Sultiple Mye	<u>eloma</u>		
Male	6.02	3	NC*	Male	3.09	3	NC*
Female	5.74	6	105	Female	2.90	3	NC*
Total	11.76	9	77	Total	5.98	6	100
Breast			No	<u>on-Hodgkin</u>	's Lymphom	<u>a</u>	
Male	0.92	1	NC*	Male	12.83	18	140
Female	106.46	101	95	Female	11.57	12	104
Total	107.38	102	95	Total	24.41	30	123
Cervix Uteri			<u>O</u> :	<u>ral Cavity a</u>	nd Pharynx		
				Male	12.10	16	132
Female	6.82	6	88	Female	5.38	8	149
				Total	17.48	24	137
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	45.20	49	108				
Female	42.65	43	101	Female	12.92	9	70
Total	87.85	92	105				
Esophagus				<u>ancreas</u>			
Male	6.00	4	NC*	Male	6.36	9	141
Female	2.12	5	235	Female	6.78	8	118
Total	8.12	9	111	Total	13.14	17	129
Hodgkin's Disc				<u>rostate</u>			
Male	2.71	0	NC*	Male	101.22	84	83
Female	2.22	5	225				
Total	4.93	5	101				
Kidney and Re				omach_			
Male	10.25	9	88	Male	7.49	8	107
Female	6.23	7	112	Female	4.65	3	NC*
Total	16.48	16	97	Total	12.14	11	91
<u>Larynx</u>				<u>estis</u>			
Male	6.55	5	76	Male	3.91	2	NC*
Female	1.84	1	NC*				
Total	8.39	6	71				
<u>Leukemia</u>	6.01	0		<u>hyroid</u>	1.50	2	Mode
Male	6.91	8	116	Male	1.70	2	NC*
Female	5.29	4	NC*	Female	4.74	5	106
Total	12.19	12	98	Total	6.44	7	109
Liver and Intra	<u>-</u>			teri, Corpus	and Uterus,	<u>NUS</u>	
Male	2.86	2	NC*	г 1	20.11	01	104
Female	1.30	4	NC*	Female	20.11	21	104
Total	4.17	6	144	11 C'4 / / T			
Lung and Bron		40	· · · · · · · · · · · · · · · · · · ·	ll Sites / Ty		225	^ ~
Male	56.94	48	84	Male	343.17	327	95

Female	40.75	34	83	Female	328.07	316	96
Total	97.69	82	84	Total	671.24	643	96

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

REHOBOTH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>rv</u>		<u>M</u>	<u>lelanoma of S</u>	<u>Skin</u>		
Male	5.82	5	86	Male	3.37	2	NC*
Female	1.90	4	NC*	Female	2.63	0	NC*
Total	7.73	9	116	Total	6.00	2	NC*
Brain and Cen	<u>tral Nervous S</u>	<u>System</u>	<u>M</u>	<u>lultiple Myel</u>	<u>oma</u>		
Male	2.31	1	NC*	Male	1.07	0	NC*
Female	2.00	1	NC*	Female	0.88	2	NC*
Total	4.31	2	NC*	Total	1.95	2	NC*
Breast		Non-Hodgkin's Lymphoma					
Male	0.33	0	NC*	Male	4.72	7	148
Female	35.80	36	101	Female	3.63	5	138
Total	36.12	36	100	Total	8.36	12	144
Cervix Uteri			<u>O</u> :	ral Cavity an	d Pharynx		
				Male	4.60	1	NC*
Female	2.52	0	NC*	Female	1.76	1	NC*
				Total	6.36	2	NC*
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	15.48	12	78				
Female	12.34	9	73	Female	4.46	2	NC*
Total	27.82	21	75				
Esophagus			<u>Pa</u>	ancreas			
Male	2.19	1	NC*	Male	2.25	0	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	0.61	1	NC*	Female	2.00	3	NC*
Total	2.80	2	NC*	Total	4.25	3	NC*
Hodgkin's Dise	ease		<u>P</u> 1	<u>rostate</u>			
Male	1.08	1	NC*	Male	33.95	21	62 #-
Female	0.85	1	NC*				
Total	1.93	2	NC*				
Kidney and Re	nal Pelvis		St	<u>omach</u>			
Male	3.77	3	NC*	Male	2.59	2	NC*
Female	2.01	0	NC*	Female	1.34	2	NC*
Total	5.79	3	NC*	Total	3.93	4	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.43	0	NC*	Male	1.59	0	NC*
Female	0.62	0	NC*				
Total	3.05	0	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	2.54	1	NC*	Male	0.68	1	NC*
Female	1.75	2	NC*	Female	1.79	0	NC*
Total	4.30	3	NC*	Total	2.46	1	NC*
Liver and Intra	hepatic Bile I	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS	
Male	1.03	0	NC*				
Female	0.40	0	NC*	Female	6.72	9	134
Total	1.43	0	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	20.22	16	79	Male	120.73	79	65 ^-
Female	13.02	17	131	Female	106.41	103	97
Total	33.23	33	99	Total	227.14	182	80 ~-

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

REVERE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases μ indicates statistical significance at the μ <= 0.05 level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Make A7.27		Exp	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Female Total 13.82 11 80 98 Total 14.41 95 25 77 Brain and Certival Nervous System Wultiple Western Male Paramatic Provincial Provinci	Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Total 51.09 50 98 Total 32.51 25 77 Make 11.72 6 51 Make 6.69 6 98 Female 11.10 10 90 Female 6.13 6 98 Total 22.82 16 70 Total 12.82 12 94 Breast Nor-Hodekin-Vembrus Make 1.95 1 NC* Make 26.15 46 176 ^4 Female 21.043 257 122 ~+ Female 23.98 25 104 Total 212.38 258 121 ~+ Total 50.12 71 142 ~+ Cerviv Uter: Deal Cavity well and the part of	Male	37.27	39	105	Male	18.10	16	88
Brain and Certinale 11.10 10 90 Female 6.13 6.69 6.90 6.90 6.90 7.00 7	Female	13.82	11	80	Female	14.41	9	62
Male Female 11.72 6 51 Male Female 6.69 6 98 Female 11.10 10 90 Female 6.13 6 98 Total 22.82 16 70 Total 12.82 12 94 Nor-Hogkin's tymphoms Male 1.95 1 NC* Male 26.15 46 176 ^^ + Female 210.43 257 122 ~+ Female 23.98 25 104 Total 212.38 258 121 ~+ Total 50.12 71 142 ~+ Cervix Uter: Male 24.11 29 120 Female 12.59 15 119 Female 24.11 29 120 Female 98.94 100 101 101 101 101 101 101 101 101 101 101 101 101 101 101 101 101	Total	51.09	50	98	Total	32.51	25	77
Female Total 11.10 10 90 Female Total 6.13 6 98 Total Total 22.82 16 70 Total Total 12.82 12 94 Breast Substitution of the production of the prod	Brain and Cen	tral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Total 22.82 16 70 Total 12.82 12 94 Breast Nor-Hodgkirs tymphoma Nor-Hodgkirs tymphoma 16 176 ^ 4 Male 1.943 257 122 ~+ Female 23.98 25 104 Femala 212.38 258 121 ~+ Total 50.12 7 142 ~+ Cervix Uteri Male 24.11 29 120 Female 12.59 15 119 Female 10.81 15 139 Female 12.59 15 119 Female 10.81 15 139 Female 12.59 15 119 Female 10.81 15 139 Female 12.59 15 109 Female 24.11 29 120 Pemale 98.94 100 101 108 12 25.10 28 112 12 12 <t< td=""><td>Male</td><td>11.72</td><td>6</td><td>51</td><td>Male</td><td>6.69</td><td>6</td><td>90</td></t<>	Male	11.72	6	51	Male	6.69	6	90
Male Male 1.95 1 NC* Male 26.15 46 176 ^+ 16	Female	11.10	10	90	Female	6.13	6	98
Male Female Pemale Pemale Pemale Pemale 210.43 1 Semale 257 122 → Female Pemale Pemale 23.98 46 176 ↑ 142 → 164 176 ↑ 142 → 176 № 180 № 176 № 180 №	Total	22.82	16	70	Total	12.82	12	94
Female Total 210.43 257 122 ~+ Female Total 23.98 25 104 ~+ Cervix Uteri Oral Cavity → Pharynx Nale 24.11 29 120 Female 12.59 15 119 Female 10.81 15 139 Female 12.59 15 119 Female 10.81 15 139 Female 12.59 15 119 Female 10.81 15 139 Colon / Rectum Ovary Male 98.94 100 101 101 120 20 28 112 20 20 28 112 20 20 20 12 20 20 20 12 20 20 20 12 20 20 20 10 20 20 20 20 20 20 20 20 20 20 20 20 20 20	Breast			N	on-Hodgkin	's Lymphoma	<u>L</u>	
Total 212.38 258 121 ~+ Total 50.12 71 142 ~+ Cervix Uteri Cervix Uteri Cervix Uteri Total 24.11 29 120 Female 12.59 15 119 Female 10.81 15 139 Female 12.59 15 119 Female 10.81 15 139 Male 98.94 100 101 Female 92.93 81 87 Female 25.10 28 112 Female 12.46 7 152 Female 13.55 11 81 28 29 103 20 <td>Male</td> <td>1.95</td> <td>1</td> <td>NC*</td> <td>Male</td> <td>26.15</td> <td>46</td> <td>176 ^+</td>	Male	1.95	1	NC*	Male	26.15	46	176 ^+
Cervix Uteri Cervix Uteris Male 24.11 29 120 Female 12.59 15 119 Female 10.81 15 139 130 Female 98.94 100 100 Total 7 Permale 25.10 28 110 110 Female 25.10 28 110 110 8 8 Female 25.10 28 110 18 87 Female 25.10 28 110 18 87 Female 25.10 28 11 8 11 8 11 8 11 8 11 8 11 8 12 Female 25.10 28 11 8 12 12 12 12 12 13 13 13 13 13 13 13 13 <th< td=""><td>Female</td><td>210.43</td><td>257</td><td>122 ~+</td><td>Female</td><td>23.98</td><td>25</td><td>104</td></th<>	Female	210.43	257	122 ~+	Female	23.98	25	104
Female 12.59 15 119 Female Female Female Female Total 10.81 15 139 Colon / Rectum Ovary Male 98.94 100 101 Female 25.10 28 112 Female 92.93 81 87 Female 25.10 28 112 Female 92.93 81 87 Female 25.10 28 112 Female 92.93 81 87 Female 25.10 28 112 Female 191.88 181 94 7 56 Male 13.55 11 81 Female 4.62 7 152 Female 14.55 18 124 Total 17.11 14 82 Total 28.10 29 103 Hodgkin's Discussor Perstate Perstate Perstate 12 96 Perstate Perstate 12 96 Perstate 12 96 </td <td>Total</td> <td>212.38</td> <td>258</td> <td>121 ~+</td> <td>Total</td> <td>50.12</td> <td>71</td> <td>142 ~+</td>	Total	212.38	258	121 ~+	Total	50.12	71	142 ~+
Female 12.59 15 119 Female 10.81 15 126 Colon / Rectum Ovary Male 98.94 100 101 Female 25.10 28 112 Female 92.93 81 87 Female 25.10 28 112 Total 191.88 181 94 7 56 Male 13.55 11 81 <td>Cervix Uteri</td> <td></td> <td></td> <td><u>O</u></td> <td>ral Cavity a</td> <td>nd Pharynx</td> <td></td> <td></td>	Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
Colon / Rectum Colon / Rectum <t< td=""><td></td><td></td><td></td><td></td><td>Male</td><td>24.11</td><td>29</td><td>120</td></t<>					Male	24.11	29	120
Colon / Rectum Male 98.94 100 101 Female 92.93 81 87 Female 25.10 28 112 Total 191.88 181 94 7 56 Male 25.10 28 112 Parteres Parteres Male 12.49 7 56 Male 13.55 11 81 Female 4.62 7 152 Female 14.55 18 124 Total 17.11 14 82 Total 28.10 29 103 Pemale 4.62 7 152 Female 14.55 18 124 Total 17.11 14 82 Total 28.10 29 103 Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* Stomach 117 117<	Female	12.59	15	119	Female	10.81	15	139
Male Female 98.94 92.93 100 81 101 88 87 Female 25.10 28 112 Total 191.88 181 94 Esophagus Parcreas Male 12.49 7 56 Male 13.55 11 81 Female 4.62 7 152 Female 14.55 18 124 Total 17.11 14 82 Total 28.10 29 103 Hodgkin's Discust Prostate Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* Total 8.91 8 90 89 Kidney and Reval Pelvis Male 21.13 25 118 Male 16.25 19 117 Female 12.60 11 87 Female 10.19 16 157 Total 33.72 36 107 Total 26.44 35 132 Larynx Testis Male 13.39 15 112 Male 6.73 10 149 Female 3.59 7 195 Male 6.73 10 149 Female 3.59 7 195 Male 6.73 10 149 Female 3.69 9 7 195 Male 6.73 10 149 Female 3.69 9 7 195 Male 6.73 10 149 Female 16.97 22 130 Male 6.73 10 149 Female 16.97 22 130 Male 6.73 10 149 Female 16.97 22 130 <td></td> <td></td> <td></td> <td></td> <td>Total</td> <td>34.92</td> <td>44</td> <td>126</td>					Total	34.92	44	126
Female 92.93 81 87 Female 25.10 28 112 Esophagus Parcreas Male 12.49 7 56 Male 13.55 11 81 Female 4.62 7 152 Female 14.55 18 124 Total 17.11 14 82 Total 28.10 29 103 Hodgkin's Discrete Provstate Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* V 224.47 215 96 Female 4.00 3 NC* V 224.47 215 96 Female 4.00 3 NC* V V 215 96 Female 21.13 25 118 Male 16.25 19 117 Female 12.60 11 87 Female <	Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Total 191.88 181 94 Esophagus Partreas Male 12.49 7 56 Male 13.55 11 81 Female 4.62 7 152 Female 14.55 18 124 Total 17.11 14 82 Total 28.10 29 103 Hodgkin's Disex Prostate Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* Total 8.91 8 90 Estimate Stomach Male 21.13 25 118 Male 16.25 19 117 Female 12.60 11 87 Female 10.19 16 157 Total 33.72 36 107 Total 26.44 35 132 Female 3.59 <td< td=""><td>Male</td><td>98.94</td><td>100</td><td>101</td><td></td><td></td><td></td><td></td></td<>	Male	98.94	100	101				
Esophagus Paucreas Male 12.49 7 56 Male 13.55 11 81 Female 4.62 7 152 Female 14.55 18 124 Total 17.11 14 82 Total 28.10 29 103 Hodgkin's Disease Perostate Perostate Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* NC* NC* 9 9 15 96 9	Female	92.93	81	87	Female	25.10	28	112
Male 12.49 7 56 Male 13.55 11 81 Female 4.62 7 152 Female 14.55 18 124 Total 17.11 14 82 Total 28.10 29 103 Hodgkin's Disease Prostate Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* NC* NC* 102 Male 224.47 215 96 Female 4.00 3 NC*	Total	191.88	181	94				
Female 4.62 7 152 Female 14.55 18 124 Total 17.11 14 82 Total 28.10 29 103 Hodgkin's Disease Prostate Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* Total 8.91 8 90 7 101 8.91 8 90 8 90 117 8.91 8 90 9 117 17 17 18 90 9 117 17 18 16 15 19 117 17 17 18 18 16 15 19 117 17 18 18 18 16 15 19 117 17 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18	Esophagus			<u>Pa</u>	ancreas			
Total 17.11 14 82 Total 28.10 29 103 Hodgkin's Disease Prostate Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* - - - - 96 Female 4.00 3 NC* -<	Male	12.49	7	56	Male	13.55	11	81
Hodgkin's Disease Perstate Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* ————————————————————————————————————	Female	4.62	7	152	Female	14.55	18	124
Male 4.91 5 102 Male 224.47 215 96 Female 4.00 3 NC* ————————————————————————————————————	Total	17.11	14	82	Total	28.10	29	103
Female Total 4.00 3 NC* Total 8.91 8 90 Kidnev and Renal Pelvis Stomach Male 21.13 25 118 Male 16.25 19 117 Female 12.60 11 87 Female 10.19 16 157 Total 33.72 36 107 Total 26.44 35 132 Larynx Testis Male 13.39 15 112 Male 6.73 10 149 Female 3.59 7 195 7 195 7 195 7 195 7 195 8 10 149 1	Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Total 8.91 8 90 Kidney and Revolvis Stomach Male 21.13 25 118 Male 16.25 19 117 Female 12.60 11 87 Female 10.19 16 157 Total 33.72 36 107 Total 26.44 35 132 Larynx Tests Male 13.39 15 112 Male 6.73 10 149 Female 3.59 7 195 7 195 7 195 7 195 7 195 8 8 10 149 1	Male	4.91	5	102	Male	224.47	215	96
Kidney and Renal Pelvis Stomach Male 21.13 25 118 Male 16.25 19 117 Female 12.60 11 87 Female 10.19 16 157 Total 33.72 36 107 Total 26.44 35 132 Larynx Testis Male 13.39 15 112 Male 6.73 10 149 Female 3.59 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 10	Female	4.00	3	NC*				
Male 21.13 25 118 Male 16.25 19 117 Female 12.60 11 87 Female 10.19 16 157 Total 33.72 36 107 Total 26.44 35 132 Testis Male 13.39 15 112 Male 6.73 10 149 Female 3.59 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 7 195 8 8 10 10 149 10 10 149 10 10 10 149 10 10 149 10 10 10 149 10 10 10	Total	8.91	8	90				
Female 12.60 11 87 Female 10.19 16 157 Total 33.72 36 107 Total 26.44 35 132 Larynx Testis Male 13.39 15 112 Male 6.73 10 149 Female 3.59 7 195 7 195 7 195 7 195 7 195 7 195 8 8 10 149 149 140 </td <td>Kidney and Re</td> <td>enal Pelvis</td> <td></td> <td><u>St</u></td> <td>omach_</td> <td></td> <td></td> <td></td>	Kidney and Re	enal Pelvis		<u>St</u>	omach_			
Total 33.72 36 107 Total 26.44 35 132 Larynx Testis Male 13.39 15 112 Male 6.73 10 149 Female 3.59 7 195 7 195 7 195 7 195 7 195 8 10 149 8 10 149<	Male	21.13	25	118	Male	16.25	19	117
Larynx Testis Male 13.39 15 112 Male 6.73 10 149 Female 3.59 7 195 7 195 7 195 7 195 8 8 10 8 10 <t< td=""><td>Female</td><td>12.60</td><td>11</td><td>87</td><td>Female</td><td>10.19</td><td>16</td><td>157</td></t<>	Female	12.60	11	87	Female	10.19	16	157
Male 13.39 15 112 Male 6.73 10 149 Female 3.59 7 195 Thyroid Thyroid Male 14.12 26 184 ~+ Male 3.17 6 189 Female 10.66 9 84 Female 8.62 9 104 Total 24.78 35 141 Total 11.79 15 127 Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS	Total	33.72	36	107	Total	26.44	35	132
Female 3.59 7 195 Total 16.97 22 130 Thyroid Male 14.12 26 184 ~+ Male 3.17 6 189 Female 10.66 9 84 Female 8.62 9 104 Total 24.78 35 141 Total 11.79 15 127 Liver and Intrabepatic Bile Ducts Uteri, Corpus and Uterus, NOS	<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Total 16.97 22 130 Leukemia Thyroid Male 14.12 26 184 ~+ Male 3.17 6 189 Female 10.66 9 84 Female 8.62 9 104 Total 24.78 35 141 Total 11.79 15 127 Liver and Intrabepatic Bile Ducts Uteri, Corpus and Uterus, NOS	Male	13.39	15	112	Male	6.73	10	149
Leukemia Thyroid Male 14.12 26 184 ~+ Male 3.17 6 189 Female 10.66 9 84 Female 8.62 9 104 Total 24.78 35 141 Total 11.79 15 127 Liver and Intrabepatic Bile Ducts Uteri, Corpus and Uterus, NOS	Female	3.59	7	195				
Male 14.12 26 184 ~+ Male 3.17 6 189 Female 10.66 9 84 Female 8.62 9 104 Total 24.78 35 141 Total 11.79 15 127 Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS	Total	16.97	22	130				
Female 10.66 9 84 Female 8.62 9 104 Total 24.78 35 141 Total 11.79 15 127 Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS	Leukemia			<u>T</u>	<u>hyroid</u>			
Total 24.78 35 141 Total 11.79 15 127 <u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri, Corpus and Uterus, NOS</u>	Male	14.12	26	184 ~+	Male	3.17	6	189
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri, Corpus and Uterus, NOS</u>	Female	10.66	9	84	Female	8.62	9	104
	Total	24.78	35	141	Total	11.79	15	127
Male 5.99 8 134	Liver and Intra	ahepatic Bile	Ducts	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
	Male	5.99	8	134				

Female	2.73	2	NC*	Female	39.69	34	86
Total	8.72	10	115				
Lung and Broi	<u>nchus</u>		<u>A</u> l	l Sites / Ty	pes		
Male	121.15	161	133 ^+	Male	732.36	809	110 ~+
Female	82.48	90	109	Female	664.53	736	111 ~+
Total	203.63	251	123 ~+	Total	1396.89	1545	111 ^+

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

RICHMOND

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of S	<u>Skin</u>			
Male	1.39	1	NC*	Male	0.74	1	NC*	
Female	0.45	1	NC*	Female	0.55	0	NC*	
Total	1.84	2	NC*	Total	1.28	1	NC*	
Brain and Cent	tral Nervous S	<u>System</u>	Multiple Myeloma					
Male	0.48	0	NC*	Male	0.25	0	NC*	
Female	0.42	0	NC*	Female	0.21	0	NC*	
Total	0.90	0	NC*	Total	0.46	0	NC*	
Breast			Non-Hodgkin's Lymphoma					
Male	0.08	0	NC*	Male	1.03	0	NC*	
Female	7.99	7	88	Female	0.81	1	NC*	
Total	8.07	7	87	Total	1.85	1	NC*	
Cervix Uteri			<u>O</u> 1	ral Cavity an	nd Pharynx			
				Male	1.02	0	NC*	
Female	0.49	0	NC*	Female	0.40	0	NC*	
				Total	1.42	0	NC*	
Colon / Rectum	<u>L</u>	<u>Ovary</u>						
Male	3.70	1	NC*					

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	2.93	4	NC*	Female	0.97	2	NC*
Total	6.62	5	75				
Esophagus			<u>Pa</u>	ancreas_			
Male	0.50	1	NC*	Male	0.52	0	NC*
Female	0.15	0	NC*	Female	0.47	0	NC*
Total	0.65	1	NC*	Total	1.00	0	NC*
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>			
Male	0.20	0	NC*	Male	8.20	10	122
Female	0.14	0	NC*				
Total	0.35	0	NC*				
Kidney and Re	<u>nal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	0.85	0	NC*	Male	0.62	0	NC*
Female	0.46	0	NC*	Female	0.32	0	NC*
Total	1.31	0	NC*	Total	0.93	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.55	0	NC*	Male	0.27	0	NC*
Female	0.14	0	NC*				
Total	0.70	0	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	0.56	0	NC*	Male	0.13	0	NC*
Female	0.37	0	NC*	Female	0.33	0	NC*
Total	0.93	0	NC*	Total	0.46	0	NC*
Liver and Intra	<u>hepatic Bile D</u>	<u>Oucts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.24	0	NC*				
Female	0.09	0	NC*	Female	1.54	1	NC*
Total	0.33	0	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>		
Male	4.70	3	NC*	Male	27.98	19	68
Female	3.02	1	NC*	Female	23.91	18	75
Total	7.72	4	NC*	Total	51.89	37	71 #-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

ROCHESTER

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	2.69	1	NC*	Male	1.54	2	NC*	
Female	0.82	0	NC*	Female	1.15	2	NC*	
Total	3.52	1	NC*	Total	2.69	4	NC*	
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>			
Male	1.07	1	NC*	Male	0.49	0	NC*	
Female	0.87	1	NC*	Female	0.37	1	NC*	
Total	1.94	2	NC*	Total	0.87	1	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>		
Male	0.15	0	NC*	Male	2.16	2	NC*	
Female	15.24	16	105	Female	1.58	1	NC*	
Total	15.39	16	104	Total	3.74	3	NC*	
Cervix Uteri			Oral Cavity and Pharynx					
				Male	2.09	0	NC*	
Female	1.12	1	NC*	Female	0.75	0	NC*	
				Total	2.84	0	NC*	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	7.14	5	70					
Female	5.38	5	93	Female	1.91	2	NC*	
Total	12.52	10	80					
Esophagus			<u>Pa</u>	ancreas				
Male	1.00	1	NC*	Male	1.03	0	NC*	
Female	0.27	0	NC*	Female	0.86	1	NC*	
Total	1.26	1	NC*	Total	1.89	1	NC*	
Hodgkin's Disc	ease_		<u>Pı</u>	<u>rostate</u>				
Male	0.50	1	NC*	Male	15.60	7	45 #-	
Female	0.40	0	NC*					
Total	0.90	1	NC*					
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>				
Male	1.72	2	NC*	Male	1.20	0	NC*	
Female	0.86	0	NC*	Female	0.59	0	NC*	
Total	2.57	2	NC*	Total	1.79	0	NC*	
<u>Larynx</u>				<u>estis</u>				
Male	1.10	1	NC*	Male	0.72	0	NC*	
Female	0.26	0	NC*					
Total	1.36	1	NC*					
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>				

Male	1.19	1	NC*	Male	0.31	0	NC*
Female	0.78	0	NC*	Female	0.81	0	NC*
Total	1.97	1	NC*	Total	1.12	0	NC*
Liver and Intra	hepatic Bile I	<u>Ducts</u>	<u>U</u> 1	t <mark>eri, Corpus</mark>	and Uterus,	NOS	
Male	0.47	0	NC*				
Female	0.17	1	NC*	Female	2.81	1	NC*
Total	0.65	1	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty	pes		
Male	9.21	16	174	Male	55.40	44	79
Female	5.43	11	202 #+	Female	45.67	46	101
Total	14.64	27	184 ~+	Total	101.06	90	89

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

ROCKLAND

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>iry</u>		<u>M</u>	elanoma of	<u>Skin</u>		
Male	11.09	13	117	Male	5.92	6	101
Female	4.37	0	NC*	Female	5.19	1	NC*
Total	15.46	13	84	Total	11.11	7	63
Brain and Cen	tral Nervous S	tral Nervous System Multiple Myeloma					
Male	4.09	4	NC*	Male	2.00	3	NC*
Female	4.00	7	175	Female	1.96	2	NC*
Total	8.09	11	136	Total	3.96	5	126
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>a_</u>	
Male	0.59	0	NC*	Male	8.60	10	116
Female	71.99	56	78	Female	7.92	4	NC*
Total	72.58	56	77	Total	16.52	14	85
Cervix Uteri			<u>O</u> :	ral Cavity aı	nd Pharynx		

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

						_	
				Male	7.74	5	65
Female	4.84	4	NC*	Female	3.66	6	164
				Total	11.40	11	97
Colon / Rectu	<u>m</u>		<u>O</u>	<u>vary</u>			
Male	29.53	30	102				
Female	28.87	34	118	Female	8.81	6	68
Total	58.40	64	110				
Esophagus			<u>Pa</u>	ancreas			
Male	3.83	4	NC*	Male	4.15	2	NC*
Female	1.45	2	NC*	Female	4.58	7	153
Total	5.28	6	114	Total	8.73	9	103
Hodgkin's Di	<u>sease</u>		<u>Pr</u>	<u>rostate</u>			
Male	1.99	1	NC*	Male	67.15	78	116
Female	1.66	1	NC*				
Total	3.64	2	NC*				
Kidney and R	<u>Renal Pelvis</u>		St	<u>omach</u>			
Male	6.67	7	105	Male	4.87	3	NC*
Female	4.24	3	NC*	Female	3.15	5	159
Total	10.91	10	92	Total	8.02	8	100
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	4.19	4	NC*	Male	2.96	2	NC*
Female	1.24	2	NC*				
Total	5.43	6	111				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	4.68	3	NC*	Male	1.18	2	NC*
Female	3.69	5	136	Female	3.41	7	206
Total	8.37	8	96	Total	4.58	9	196
Liver and Int	rahepatic Bile	<u>Ducts</u>	<u>U1</u>	teri, Corpus	s and Uteru	is, NOS	
Male	1.87	2	NC*	_			
Female	0.90	0	NC*	Female	13.51	6	44 #-
Total	2.77	2	NC*				
Lung and Bro	nchus_		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	37.07	42	113	Male	226.27	234	103
Female	27.49	31	113	Female	223.09	212	95
Total	64.56	73	113	Total	449.36	446	99

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

ROCKPORT

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>[elanoma of</u>	<u>Skin</u>			
Male	7.52	5	67	Male	3.56	4	NC*	
Female	3.28	2	NC*	Female	3.14	3	NC*	
Total	10.80	7	65	Total	6.70	7	104	
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	2.24	1	NC*	Male	1.34	1	NC*	
Female	2.44	2	NC*	Female	1.43	0	NC*	
Total	4.68	3	NC*	Total	2.77	1	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>		
Male	0.39	0	NC*	Male	5.12	6	117	
Female	46.70	47	101	Female	5.54	5	90	
Total	47.09	47	100	Total	10.66	11	103	
Cervix Uteri		Oral Cavity and Pharynx						
				Male	4.75	5	105	
Female	2.66	1	NC*	Female	2.44	3	NC*	
				Total	7.19	8	111	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	19.88	22	111					
Female	22.26	18	81	Female	5.50	7	127	
Total	42.15	40	95					
Esophagus			<u>Pa</u>	ancreas				
Male	2.48	1	NC*	Male	2.69	6	223	
Female	1.11	1	NC*	Female	3.44	5	145	
Total	3.59	2	NC*	Total	6.14	11	179	
Hodgkin's Disc	ease			<u>rostate</u>				
Male	0.90	2	NC*	Male	44.64	38	85	
Female	0.84	1	NC*					
Total	1.74	3	NC*					
Kidney and Re	<u>nal Pelvis</u>		<u>St</u>	omach_				
Male	4.14	3	NC*	Male	3.29	3	NC*	
Female	2.85	2	NC*	Female	2.45	2	NC*	
Total	6.99	5	72	Total	5.74	5	87	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	2.64	1	NC*	Male	1.21	4	NC*
Female	0.79	0	NC*				
Total	3.43	1	NC*				
Leukemia			<u>Tł</u>	<u>iyroid</u>			
Male	2.74	1	NC*	Male	0.60	0	NC*
Female	2.43	2	NC*	Female	1.80	1	NC*
Total	5.17	3	NC*	Total	2.40	1	NC*
Liver and Intrahepatic Bile Ducts				t <mark>eri, Corpus</mark>	and Uterus	NOS	
Male	1.18	1	NC*				
Female	0.64	3	NC*	Female	8.78	16	182 #+
Total	1.82	4	NC*				
Lung and Drag	_		A 1	I Sitos / Tr	noc		
Lung and Broi	<u>nchus</u>		<u>A</u> J	<u>ll Sites / Ty</u>	<u>nes</u>		
Male	<u>nchus</u> 23.91	12	50 #-	Male	145.10	121	83 #-
		12 24				121 153	83 #- 102
Male	23.91		50 #-	Male	145.10		

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

ROWE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR		
Bladder, Urinar	<u>v</u>	Melanoma of Skin							
Male	0.40	1	NC*	Male	0.19	0	NC*		
Female	0.11	0	NC*	Female	0.13	0	NC*		
Total	0.50	1	NC*	Total	0.31	0	NC*		
Brain and Central Nervous System			$\underline{\mathbf{M}}$	<u>lultiple Myel</u>	<u>oma</u>				
Male	0.12	1	NC*	Male	0.07	0	NC*		
Female	0.10	0	NC*	Female	0.05	0	NC*		
Total	0.21	1	NC*	Total	0.12	0	NC*		
Breast			N	on-Hodgkin's	s Lymphoma	1			

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	0.02	0	NC*	Male	0.27	2	NC*
Female	1.87	1	NC*	Female	0.19	0	NC*
Total	1.89	1	NC*	Total	0.46	2	NC*
Cervix Uteri			<u>O</u> :	ral Cavity ar	nd Pharynx		
				Male	0.25	0	NC*
Female	0.11	0	NC*	Female	0.09	0	NC*
				Total	0.35	0	NC*
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	1.04	1	NC*				
Female	0.69	3	NC*	Female	0.22	0	NC*
Total	1.73	4	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.13	0	NC*	Male	0.14	0	NC*
Female	0.04	0	NC*	Female	0.11	0	NC*
Total	0.17	0	NC*	Total	0.25	0	NC*
Hodgkin's Dise	ease_		<u>Pr</u>	<u>rostate</u>			
Male	0.05	0	NC*	Male	2.26	1	NC*
Female	0.03	0	NC*				
Total	0.08	0	NC*				
Kidney and Rea	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	0.22	0	NC*	Male	0.17	0	NC*
Female	0.11	1	NC*	Female	0.07	0	NC*
Total	0.33	1	NC*	Total	0.25	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.14	0	NC*	Male	0.06	0	NC*
Female	0.03	0	NC*				
Total	0.17	0	NC*				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	0.14	0	NC*	Male	0.03	0	NC*
Female	0.08	0	NC*	Female	0.07	0	NC*
Total	0.23	0	NC*	Total	0.11	0	NC*
Liver and Intra	hepatic Bile D	<u>ucts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	0.06	0	NC*				
Female	0.02	0	NC*	Female	0.37	0	NC*
Total	0.08	0	NC*				
Lung and Brone	<u>chus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>		
Male	1.23	2	NC*	Male	7.50	8	107
Female	0.75	1	NC*	Female	5.64	6	106
Total	1.98	3	NC*	Total	13.14	14	107

 $\mathbf{Exp} = \text{expected case count}$, based on the Massachusetts average age-specific incidence rates for this cancer $\mathbf{Obs} = \text{observed case count}$

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

ROWLEY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	2.67	2	NC*	Male	1.58	2	NC*	
Female	0.98	2	NC*	Female	1.29	2	NC*	
Total	3.65	4	NC*	Total	2.87	4	NC*	
Brain and Cent	tral Nervous	<u>System</u>	<u>M</u>	Multiple Myeloma				
Male	1.11	2	NC*	Male	0.49	0	NC*	
Female	0.96	1	NC*	Female	0.43	0	NC*	
Total	2.07	3	NC*	Total	0.92	0	NC*	
Breast			No	on-Hodgkin'	s Lymphoma	<u>1</u>		
Male	0.15	0	NC*	Male	2.25	2	NC*	
Female	16.76	14	84	Female	1.83	1	NC*	
Total	16.91	14	83	Total	4.09	3	NC*	
Cervix Uteri			<u>O</u> :	ral Cavity ar	<u>nd Pharynx</u>			
				Male	2.05	1	NC*	
Female	1.25	1	NC*	Female	0.84	2	NC*	
				Total	2.89	3	NC*	
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	7.04	6	85					
Female	6.52	5	77	Female	2.10	2	NC*	
Total	13.57	11	81					
Esophagus			<u>Pa</u>	ancreas				
Male	0.96	0	NC*	Male	1.00	1	NC*	
Female	0.32	0	NC*	Female	1.01	0	NC*	
Total	1.28	0	NC*	Total	2.01	1	NC*	
Hodgkin's Dis	<u>ease</u>		<u>Pı</u>	<u>rostate</u>				
Male	0.59	0	NC*	Male	14.74	7	47 #-	
Female	0.45	1	NC*					
Total	1.04	1	NC*					

Kidney and R	enal Pelvis		St	<u>omach</u>			
Male	1.67	0	NC*	Male	1.21	0	NC*
Female	0.95	0	NC*	Female	0.73	0	NC*
Total	2.62	0	NC*	Total	1.94	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.06	1	NC*	Male	0.91	3	NC*
Female	0.27	0	NC*				
Total	1.33	1	NC*				
Leukemia			<u>T</u>	<u>nyroid</u>			
Male	1.22	1	NC*	Male	0.34	1	NC*
Female	0.90	0	NC*	Female	0.91	1	NC*
Total	2.12	1	NC*	Total	1.25	2	NC*
Liver and Intr	ahepatic Bile	Ducts	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
Male	0.46	1	NC*				
Female	0.20	0	NC*	Female	3.02	5	166
Total	0.66	1	NC*				
Lung and Bro	nchus_		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	8.75	12	137	Male	54.41	45	83
Female	5.88	6	102	Female	51.38	47	91
Total	14.63	18	123	Total	105.79	92	87

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

ROYALSTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary			$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>		
Male	0.88	1	NC*	Male	0.45	0	NC*
Female	0.29	0	NC*	Female	0.32	0	NC*
Total	1.18	1	NC*	Total	0.77	0	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Brain and Centr	al Nervous S	<u>System</u>	Multiple Myeloma				
Male	0.31	0	NC*	Male	0.16	0	NC*
Female	0.25	0	NC*	Female	0.13	0	NC*
Total	0.56	0	NC*	Total	0.29	0	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>ı</u>	
Male	0.05	0	NC*	Male	0.66	0	NC*
Female	4.49	6	134	Female	0.52	0	NC*
Total	4.54	6	132	Total	1.18	0	NC*
Cervix Uteri			<u>O</u>	ral Cavity ar	<u>nd Pharynx</u>		
				Male	0.59	1	NC*
Female	0.29	0	NC*	Female	0.23	0	NC*
				Total	0.82	1	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	2.35	1	NC*				
Female	1.97	1	NC*	Female	0.54	1	NC*
Total	4.32	2	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.30	0	NC*	Male	0.32	0	NC*
Female	0.10	0	NC*	Female	0.31	1	NC*
Total	0.40	0	NC*	Total	0.63	1	NC*
Hodgkin's Disea	<u>ise</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.15	0	NC*	Male	5.30	0	NC*
Female	0.10	0	NC*				
Total	0.25	0	NC*				
Kidney and Ren	al Pelvis		<u>St</u>	omach_			
Male	0.51	0	NC*	Male	0.39	0	NC*
Female	0.27	0	NC*	Female	0.22	0	NC*
Total	0.79	0	NC*	Total	0.60	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.32	0	NC*	Male	0.21	0	NC*
Female	0.08	0	NC*				
Total	0.40	0	NC*				
<u>Leukemia</u>				<u>hyroid</u>			
Male	0.36	0	NC*	Male	0.09	0	NC*
Female	0.24	0	NC*	Female	0.20	0	NC*
Total	0.61	0	NC*	Total	0.29	0	NC*
Liver and Intrah	_	<u>Ducts</u>		<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.15	0	NC*				
Female	0.06	0	NC*	Female	0.84	0	NC*
Total	0.20	0	NC*				
Lung and Bronc			_	ll Sites / Typ			
Male	2.88	1	NC*	Male	17.66	4	NC*
Female	1.76	0	NC*	Female	14.29	10	70
Total	4.64	1	NC*	Total	31.95	14	44 ^-

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

RUSSELL

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		$\underline{\mathbf{Exp}}$	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	ry		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	1.03	2	NC*	Male	0.59	0	NC*
Female	0.34	0	NC*	Female	0.46	0	NC*
Total	1.36	2	NC*	Total	1.05	0	NC*
Brain and Central Nervous System				ultiple Myel	<u>oma</u>		
Male	0.41	0	NC*	Male	0.19	0	NC*
Female	0.35	0	NC*	Female	0.15	0	NC*
Total	0.76	0	NC*	Total	0.34	0	NC*
Breast			No	on-Hodgkin's	s Lymphoma	<u>1</u>	
Male	0.06	0	NC*	Male	0.84	0	NC*
Female	6.06	2	NC*	Female	0.64	0	NC*
Total	6.12	2	NC*	Total	1.48	0	NC*
Cervix Uteri			<u>O</u> 1	ral Cavity an	d Pharynx		
				Male	0.78	2	NC*
Female	0.45	0	NC*	Female	0.30	0	NC*
				Total	1.08	2	NC*
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	2.73	3	NC*				
Female	2.19	0	NC*	Female	0.76	1	NC*
Total	4.92	3	NC*				
Esophagus			<u>Pa</u>	<u>ncreas</u>			
Male	0.37	0	NC*	Male	0.39	0	NC*
Female	0.11	0	NC*	Female	0.35	0	NC*
Total	0.48	0	NC*	Total	0.74	0	NC*

Hodgkin's Dis	<u>ease</u>		Prostate				
Male	0.20	1	NC*	Male	5.99	2	NC*
Female	0.16	0	NC*				
Total	0.36	1	NC*				
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	0.65	0	NC*	Male	0.46	0	NC*
Female	0.35	1	NC*	Female	0.24	1	NC*
Total	1.00	1	NC*	Total	0.70	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.41	1	NC*	Male	0.30	0	NC*
Female	0.10	0	NC*				
Total	0.51	1	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>iyroid</u>			
Male	0.45	0	NC*	Male	0.12	0	NC*
Female	0.32	0	NC*	Female	0.32	0	NC*
Total	0.77	0	NC*	Total	0.44	0	NC*
Liver and Intr	<u>ahepatic Bile D</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.18	0	NC*				
Female	0.07	0	NC*	Female	1.12	1	NC*
Total	0.25	0	NC*				
Lung and Bron	<u>A</u>]	ll Sites / Typ	<u>oes</u>				
Male	3.49	5	143	Male	21.17	17	80
Female	2.22	2	NC*	Female	18.37	8	44 #-
Total	5.71	7	123	Total	39.55	25	63 #-

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

RUTLAND

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u>

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Bladder, Urinar	<u>y</u>		<u>M</u>	lelanoma of	<u>Skin</u>		
Male	2.61	0	NC*	Male	1.58	2	NC*
Female	0.97	2	NC*	Female	1.31	0	NC*
Total	3.58	2	NC*	Total	2.89	2	NC*
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	ultiple Mye			
Male	1.14	2	NC*	Male	0.48	0	NC*
Female	0.99	1	NC*	Female	0.44	0	NC*
Total	2.14	3	NC*	Total	0.92	0	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>1</u>	
Male	0.15	0	NC*	Male	2.26	3	NC*
Female	17.27	27	156 #+	Female	1.84	1	NC*
Total	17.42	27	155 #+	Total	4.10	4	NC*
Cervix Uteri			<u>O</u>	ral Cavity ar	nd Pharynx		
				Male	2.04	2	NC*
Female	1.28	0	NC*	Female	0.85	0	NC*
				Total	2.89	2	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	6.90	8	116				
Female	6.38	9	141	Female	2.16	1	NC*
Total	13.28	17	128				
Esophagus			<u>Pa</u>	ancreas			
Male	0.95	3	NC*	Male	0.99	0	NC*
Female	0.31	0	NC*	Female	1.01	1	NC*
Total	1.27	3	NC*	Total	2.00	1	NC*
Hodgkin's Dise	<u>ase</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.61	0	NC*	Male	14.59	19	130
Female	0.46	1	NC*				
Total	1.07	1	NC*				
Kidney and Rei	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	1.68	5	298	Male	1.18	2	NC*
Female	0.98	2	NC*	Female	0.70	0	NC*
Total	2.66	7	263 #+	Total	1.88	2	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.05	1	NC*	Male	0.94	1	NC*
Female	0.29	0	NC*				
Total	1.33	1	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	1.25	1	NC*	Male	0.35	0	NC*
Female	0.91	0	NC*	Female	0.92	1	NC*
Total	2.15	1	NC*	Total	1.27	1	NC*
Liver and Intra	hepatic Bile	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	0.46	1	NC*				
Female	0.20	0	NC*	Female	3.17	1	NC*
Total	0.66	1	NC*				

Lung and Bron		All Sites / Types						
Male	8.72	12	138	Male	54.07	68	126	
Female	6.22	2	NC*	Female	52.43	56	107	
Total	14.94	14	94	Total	106.49	124	116	

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

SALEM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>		
Male	27.85	24	86	Male	14.69	19	129
Female	11.87	7	59	Female	13.61	15	110
Total	39.72	31	78	Total	28.30	34	120
Brain and Cen	tral Nervous	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>		
Male	9.83	13	132	Male	5.02	1	NC*
Female	10.26	17	166	Female	5.26	6	114
Total	20.10	30	149 #+	Total	10.29	7	68
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	•	
Male	1.48	0	NC*	Male	21.43	29	135
Female	187.52	220	117 #+	Female	21.32	26	122
Total	189.01	220	116 #+	Total	42.76	55	129
Cervix Uteri			<u>O</u> 1	ral Cavity ar	<u>nd Pharynx</u>		
				Male	18.73	21	112
Female	12.68	13	102	Female	9.49	17	179 #+
				Total	28.22	38	135
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	73.90	82	111				
Female	79.80	83	104	Female	22.83	30	131
Total	153.70	165	107				

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Esophagus]	Pancreas				
Male	9.36	13	139	Male	10.19	14	137	
Female	3.94	5	127	Female	12.51	15	120	
Total	13.30	18	135	Total	22.70	29	128	
Hodgkin's Dis	sease_]	<u>Prostate</u>				
Male	4.92	6	122	Male	164.19	162	99	
Female	4.39	8	182					
Total	9.31	14	150					
Kidney and R	enal Pelvis	al Pelvis Stomach						
Male	16.20	15	93	Male	12.27	13	106	
Female	11.08	16	144	Female	8.77	16	183 #+	
Total	27.28	31	114	Total	21.04	29	138	
<u>Larynx</u>			, -	<u> Festis</u>				
Male	10.05	6	60	Male	7.68	8	104	
Female	3.08	5	162					
Total	13.13	11	84					
<u>Leukemia</u>			-	<u> Thyroid</u>				
Male	11.29	6	53	Male	2.94	5	170	
Female	9.72	18	185 #+	Female	8.96	7	78	
Total	21.02	24	114	Total	11.91	12	101	
Liver and Intr	ahepatic Bi		-	<u>Uteri, Corpu</u>	s and Uteru	is, NOS		
Male	4.57	5	109					
Female	2.39	1	NC*	Female	34.61	38	110	
Total	6.96	6	86					
Lung and Bro	<u>nchus</u>	<u>All Sites / Types</u>						
Male	90.15	131	145 ^+	Male	556.72	624	112 ~+	
Female	71.59	100	140 ~+	Female	589.29	708	120 ^+	
Total	161.73	231	143 ^+	Total	1146.01	1332	116 ^+	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SALISBURY

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Cancer Incidence by Sex, 1990 - 1995 Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urinar	<u> Y</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>			
Male	4.89	3	NC*	Male	2.73	6	220	
Female	1.64	0	NC*	Female	2.11	4	NC*	
Total	6.54	3	NC*	Total	4.84	10	207	
Brain and Cent	ral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>			
Male	1.85	1	NC*	Male	0.89	0	NC*	
Female	1.62	4	NC*	Female	0.75	0	NC*	
Total	3.47	5	144	Total	1.64	0	NC*	
Breast			N	<u>on-Hodgkin</u>	's Lymphoma	<u>1</u>		
Male	0.27	0	NC*	Male	3.85	4	NC*	
Female	29.15	34	117	Female	3.06	5	163	
Total	29.42	34	116	Total	6.92	9	130	
Cervix Uteri			Oral Cavity and Pharynx					
				Male	3.70	7	189	
Female	1.99	7	351 ~+	Female	1.46	2	NC*	
				Total	5.16	9	174	
Colon / Rectum	<u>-</u>		<u>O</u>	<u>vary</u>				
Male	13.03	14	107					
Female	10.72	19	177 #+	Female	3.60	3	NC*	
Total	23.75	33	139					
Esophagus			<u>Pa</u>	ancreas				
Male	1.79	3	NC*	Male	1.88	1	NC*	
Female	0.54	0	NC*	Female	1.73	1	NC*	
Total	2.33	3	NC*	Total	3.61	2	NC*	
Hodgkin's Dise	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	0.86	0	NC*	Male	29.34	30	102	
Female	0.67	0	NC*					
Total	1.53	0	NC*					
Kidney and Re	<u>nal Pelvis</u>		St	omach_				
Male	3.09	6	194	Male	2.16	4	NC*	
Female	1.68	3	NC*	Female	1.16	2	NC*	
Total	4.77	9	189	Total	3.32	6	181	
<u>Larynx</u>			$\underline{\mathbf{T}}$	<u>estis</u>				
Male	1.99	1	NC*	Male	1.26	3	NC*	
Female	0.51	2	NC*					
Total	2.50	3	NC*					
<u>Leukemia</u>				<u>hyroid</u>				
Male	2.07	3	NC*	Male	0.54	0	NC*	
Female	1.44	3	NC*	Female	1.40	0	NC*	

Total	3.50	6	171	Total	1.94	0	NC*	
Liver and Intrahepatic Bile Ducts				t <mark>eri, Corpus</mark>	and Uterus	NOS		
Male	0.85	0	NC*					
Female	0.34	0	NC*	Female	5.52	6	109	
Total	1.20	0	NC*					
Lung and Bronchus			<u>A</u>]	All Sites / Types				
Male	16.90	25	148	Male	101.09	124	123 #+	
Female	11.00	20	182 #+	Female	88.29	122	138 ^+	
Total	27.90	45	161 ~+	Total	189.38	246	130 ^+	

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

SANDISFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>			
Bladder, Urinar	<u>y</u>	Melanoma of Skin								
Male	0.80	0	NC*	Male	0.38	1	NC*			
Female	0.18	0	NC*	Female	0.20	0	NC*			
Total	0.99	0	NC*	Total	0.58	1	NC*			
Brain and Cent	ral Nervous S	<u>vstem</u>	<u>M</u>	ultiple Mye	<u>loma</u>					
Male	0.24	0	NC*	Male	0.14	0	NC*			
Female	0.16	1	NC*	Female	0.08	0	NC*			
Total	0.40	1	NC*	Total	0.23	0	NC*			
Breast			No	on-Hodgkin'	s Lymphoma	<u>1</u>				
Male	0.04	0	NC*	Male	0.54	0	NC*			
Female	2.91	1	NC*	Female	0.32	0	NC*			
Total	2.95	1	NC*	Total	0.87	0	NC*			
Cervix Uteri		Oral Cavity and Pharynx								
				Male	0.53	0	NC*			
Female	0.18	2	NC*	Female	0.15	0	NC*			

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Total	0.68	0	NC*
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	2.14	0	NC*				
Female	1.22	0	NC*	Female	0.35	1	NC*
Total	3.36	0	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.28	1	NC*	Male	0.30	0	NC*
Female	0.06	0	NC*	Female	0.20	0	NC*
Total	0.34	1	NC*	Total	0.50	0	NC*
Hodgkin's Dis	<u>ease</u>		<u>Pr</u>	<u>rostate</u>			
Male	0.09	0	NC*	Male	5.16	0	NC*
Female	0.06	0	NC*				
Total	0.15	0	NC*				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	0.47	0	NC*	Male	0.35	0	NC*
Female	0.18	0	NC*	Female	0.13	1	NC*
Total	0.64	0	NC*	Total	0.48	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.31	0	NC*	Male	0.11	0	NC*
Female	0.05	0	NC*				
Total	0.36	0	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	0.29	0	NC*	Male	0.06	0	NC*
Female	0.14	0	NC*	Female	0.12	0	NC*
Total	0.44	0	NC*	Total	0.18	0	NC*
Liver and Intra	<u>ahepatic Bile D</u>	<u>ucts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.13	0	NC*				
Female	0.04	0	NC*	Female	0.56	0	NC*
Total	0.17	0	NC*				
Lung and Bron	<u>ichus</u>		$\underline{\mathbf{A}}$	ll Sites / Typ	<u>oes</u>		
Male	2.75	2	NC*	Male	16.17	6	37 ~-
Female	1.17	2	NC*	Female	9.12	10	110
Total	3.92	4	NC*	Total	25.29	16	63

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SANDWICH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	13.63	17	125	Male	6.95	6	86	
Female	4.78	4	NC*	Female	5.50	10	182	
Total	18.41	21	114	Total	12.45	16	128	
Brain and Cent	tral Nervous	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	4.69	3	NC*	Male	2.45	3	NC*	
Female	4.26	3	NC*	Female	2.14	1	NC*	
Total	8.95	6	67	Total	4.59	4	NC*	
Breast			No	on-Hodgkin'	s Lymphoma	<u>1</u>		
Male	0.72	1	NC*	Male	10.06	10	99	
Female	77.52	89	115	Female	8.59	9	105	
Total	78.24	90	115	Total	18.65	19	102	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	9.17	5	55	
Female	5.02	4	NC*	Female	3.93	3	NC*	
				Total	13.10	8	61	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	36.16	20	55 ~-					
Female	31.89	30	94	Female	9.43	7	74	
Total	68.05	50	73 #-					
Esophagus			<u>Pa</u>	ancreas				
Male	4.63	3	NC*	Male	5.01	5	100	
Female	1.58	2	NC*	Female	5.04	3	NC*	
Total	6.22	5	80	Total	10.05	8	80	
Hodgkin's Disc	ease_		<u>P</u> 1	<u>rostate</u>				
Male	2.14	1	NC*	Male	81.48	94	115	
Female	1.70	0	NC*					
Total	3.84	1	NC*					
Kidney and Re	nal Pelvis		St	<u>omach</u>				
Male	7.93	9	113	Male	5.98	3	NC*	
Female	4.58	6	131	Female	3.49	0	NC*	
Total	12.51	15	120	Total	9.47	3	NC*	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				
Male	5.01	4	NC*	Male	3.05	1	NC*	

Female	1.32	2	NC*						
Total	6.33	6	95						
Leukemia			<u>Tl</u>	<u>nyroid</u>					
Male	5.51	7	127	Male	1.30	2	NC*		
Female	3.99	6	150	Female	3.52	7	199		
Total	9.50	13	137	Total	4.82	9	187		
Liver and Intra	ahepatic Bile l	<u>Ducts</u>	<u>U</u> 1	NOS					
Male	2.24	0	NC*						
Female	0.97	1	NC*	Female	14.54	11	76		
Total	3.21	1	NC*						
Lung and Bron	<u>chus</u>		All Sites / Types						
Male	44.58	42	94	Male	271.78	262	96		
Female	29.71	33	111	Female	241.17	249	103		
Total	74.30	75	101	Total	512.95	511	100		

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SAUGUS

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>		
Male	21.72	23	106	Male	10.94	9	82
Female	8.39	15	179 #+	Female	9.15	6	66
Total	30.10	38	126	Total	20.09	15	75
Brain and Cen	tral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>		
Male	7.11	6	84	Male	3.92	5	127
Female	7.02	7	100	Female	3.76	3	NC*
Total	14.13	13	92	Total	7.68	8	104
Breast			No	on-Hodgkin'	s Lymphoma	<u>a</u> _	
Male	1.15	3	NC*	Male	15.67	19	121

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the p <= 0.01 level, as well as at the p <= 0.05 level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	132.72	154	116	Female	14.77	21	142		
Total	133.87	157	117	Total	30.44	40	131		
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx	<u>-</u>			
				Male	14.64	14	96		
Female	8.12	9	111	Female	6.76	2	NC*		
				Total	21.40	16	75		
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>					
Male	57.62	54	94						
Female	56.02	63	112	Female	15.93	16	100		
Total	113.64	117	103						
Esophagus			<u>Pa</u>	<u>ancreas</u>					
Male	7.44	6	81	Male	7.96	17	214 ~+		
Female	2.79	3	NC*	Female	8.86	13	147		
Total	10.23	9	88	Total	16.82	30	178 ~+		
Hodgkin's Disease Prostate									
Male	3.05	3	NC*	Male	128.92	128	99		
Female	2.58	7	272 #+						
Total	5.63	10	178						
Kidney and Re									
Male	12.60	14	111	Male	9.52	7	74		
Female	7.88	9	114	Female	6.11	3	NC*		
Total	20.48	23	112	Total	15.62	10	64		
<u>Larynx</u>			<u>T</u>	<u>estis</u>					
Male	8.02	5	62	Male	4.30	6	140		
Female	2.29	1	NC*						
Total	10.31	6	58						
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>					
Male	8.39	11	131	Male	1.97	5	253		
Female	6.58	5	76	Female	5.57	6	108		
Total	14.97	16	107	Total	7.55	11	146		
Liver and Intra	_			<u>teri, Corpus</u>	s and Uterus	s, NOS			
Male	3.55	6	169						
Female	1.68	2	NC*	Female	25.14	25	99		
Total	5.22	8	153						
Lung and Bron				ll Sites / Ty	_				
Male	71.15	84	118	Male	429.36	451	105		
Female	51.85	74	143 ~+	Female	414.25	471	114 ~+		
Total	123.01	158	128 ~+	Total	843.61	922	109 ~+		

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SAVOY Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinary	<u>y</u>		<u>M</u>	elanoma of S	<u>Skin</u>				
Male	0.42	1	NC*	Male	0.25	0	NC*		
Female	0.12	0	NC*	Female	0.18	0	NC*		
Total	0.54	1	NC*	Total	0.43	0	NC*		
Brain and Centr	al Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>				
Male	0.17	0	NC*	Male	0.08	0	NC*		
Female	0.14	0	NC*	Female	0.06	0	NC*		
Total	0.31	0	NC*	Total	0.13	0	NC*		
Breast			No	on-Hodgkin's	s Lymphoma	<u>1</u>			
Male	0.02	0	NC*	Male	0.35	0	NC*		
Female	2.41	0	NC*	Female	0.24	0	NC*		
Total	2.43	0	NC*	Total	0.59	0	NC*		
<u>Cervix Uteri</u>			Oral Cavity and Pharynx						
				Male	0.33	0	NC*		
Female	0.17	0	NC*	Female	0.12	0	NC*		
				Total	0.44	0	NC*		
Colon / Rectum			<u>O</u>	<u>vary</u>					
Male	1.12	1	NC*						
Female	0.78	0	NC*	Female	0.30	0	NC*		
Total	1.90	1	NC*						
Esophagus				ncreas					
Male	0.16	0	NC*	Male	0.16	1	NC*		
Female	0.04	0	NC*	Female	0.13	0	NC*		
Total	0.19	0	NC*	Total	0.29	1	NC*		
Hodgkin's Disea	<u>ase</u>		<u>P1</u>	<u>ostate</u>					
Male	0.09	0	NC*	Male	2.50	3	NC*		
Female	0.06	0	NC*						
Total	0.15	0	NC*						
Kidney and Ren	al Pelvis			<u>omach</u>					
Male	0.27	0	NC*	Male	0.19	0	NC*		

Female	0.13	0	NC*	Female	0.08	0	NC*
Total	0.41	0	NC*	Total	0.27	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.17	0	NC*	Male	0.13	0	NC*
Female	0.04	0	NC*				
Total	0.21	0	NC*				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	0.19	1	NC*	Male	0.05	0	NC*
Female	0.12	0	NC*	Female	0.12	0	NC*
Total	0.30	1	NC*	Total	0.18	0	NC*
Liver and Intra	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_			
Male	0.07	0	NC*				
Female	0.03	0	NC*	Female	0.45	0	NC*
Total	0.10	0	NC*				
Lung and Brond	<u>chus</u>		<u>A</u>]	ll Sites / Tyr	<u>oes</u>		
Male	1.46	4	NC*	Male	8.83	11	125
Female	0.88	1	NC*	Female	7.08	2	NC*
Total	2.34	5	214	Total	15.91	13	82

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

SCITUATE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>rv</u>		Melanoma of Skin						
Male	12.67	6	47	Male	6.76	8	118		
Female	4.74	6	127	Female	5.61	7	125		
Total	17.41	12	69	Total	12.37	15	121		
Brain and Central Nervous System			$\underline{\mathbf{M}}$	<u>lultiple Mye</u>					
Male	4.51	3	NC*	Male	2.31	1	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	4.29	4	NC*	Female	2.14	3	NC*
Total	8.80	7	80	Total	4.45	4	NC*
Breast]	Non-Hodgkii	n's Lympho	<u>oma</u>	
Male	0.69	0	NC*	Male	9.54	12	126
Female	80.03	90	112	Female	8.54	11	129
Total	80.72	90	112	Total	18.09	23	127
<u>Cervix Uteri</u>			2	Oral Cavity a	and Pharyr	<u>IX</u>	
				Male	9.25	5	54
Female	5.09	5	98	Female	4.04	4	NC*
				Total	13.29	9	68
Colon / Rectur			-	<u>Ovary</u>			
Male	33.74	43	127				
Female	31.26	31	99	Female	9.73	17	175 #+
Total	65.00	74	114				
Esophagus			-	<u>Pancreas</u>			
Male	4.57	7	153	Male	4.80	9	187
Female	1.56	3	NC*	Female	4.98	4	NC*
Total	6.13	10	163	Total	9.78	13	133
Hodgkin's Di			-	<u>Prostate</u>			
Male	1.95	0	NC*	Male	76.28	113	148 ^+
Female	1.62	2	NC*				
Total	3.57	2	NC*				
Kidney and R			-	Stomach_			
Male	7.80	6	77	Male	5.57	2	NC*
Female	4.63	4	NC*	Female	3.41	4	NC*
Total	12.44	10	80	Total	8.98	6	67
<u>Larynx</u>				<u>Testis</u>			
Male	5.03	4	NC*	Male	2.74	3	NC*
Female	1.40	1	NC*				
Total	6.43	5	78				
<u>Leukemia</u>			-	Thyroid			N. Cali
Male	5.15	2	NC*	Male	1.26	3	NC*
Female	3.92	8	204	Female	3.52	8	227
Total	9.07	10	110	Total	4.78	11	230 #+
Liver and Int	<u>-</u>		-	<u>Uteri, Corpu</u>	is and Uter	us, NOS	
Male	2.17	1	NC*	ъ 1	15.16	10	105
Female	0.96	0	NC*	Female	15.16	19	125
Total	3.13	1	NC*	A 11 C!4 / TI-			
Lung and Bro		47	_	All Sites / Ty	_	200	11с 4.
Male	43.35	47	108	Male	258.04	299	116 #+
Female	30.27	29 76	96 102	Female Total	244.42	276 575	113
Total	73.63	76	103	Total	502.46	575	114 ~+

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SEEKONK

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>rv</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	10.07	13	129	Male	5.38	3	NC*	
Female	3.61	6	166	Female	4.25	4	NC*	
Total	13.68	19	139	Total	9.63	7	73	
Brain and Cent	tral Nervous	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>			
Male	3.61	2	NC*	Male	1.83	1	NC*	
Female	3.29	2	NC*	Female	1.63	4	NC*	
Total	6.90	4	NC*	Total	3.46	5	144	
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>1</u>		
Male	0.54	1	NC*	Male	7.63	8	105	
Female	60.44	59	98	Female	6.53	9	138	
Total	60.99	60	98	Total	14.16	17	120	
Cervix Uteri			Oral Cavity and Pharynx					
				Male	7.32	4	NC*	
Female	3.88	1	NC*	Female	3.06	1	NC*	
				Total	10.38	5	48	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	26.80	24	90					
Female	23.88	30	126	Female	7.35	7	95	
Total	50.68	54	107					
Esophagus			<u>Pa</u>	ancreas				
Male	3.61	4	NC*	Male	3.82	3	NC*	
Female	1.19	2	NC*	Female	3.81	2	NC*	
Total	4.80	6	125	Total	7.63	5	66	
Hodgkin's Disc	<u>ease</u>		<u>Pr</u>	<u>costate</u>				

Male	1.60	3	NC*	Male	60.83	43	71 #-
Female	1.27	4	NC*				
Total	2.87	7	244				
Kidney and R	Renal Pelvis		<u>St</u>	<u>omach</u>			
Male	6.18	5	81	Male	4.42	3	NC*
Female	3.54	2	NC*	Female	2.59	1	NC*
Total	9.73	7	72	Total	7.02	4	NC*
<u>Larynx</u>			<u>T</u> 6	<u>estis</u>			
Male	3.98	3	NC*	Male	2.28	2	NC*
Female	1.05	3	NC*				
Total	5.04	6	119				
Leukemia			<u>T</u>	<u>ayroid</u>			
Male	4.12	8	194	Male	1.02	1	NC*
Female	3.01	3	NC*	Female	2.70	1	NC*
Total	7.13	11	154	Total	3.71	2	NC*
Liver and Int	rahepatic Bile l	Ducts	Uteri, Corpus and Uterus, NOS				
Male	1.72	1	NC*				
Female	0.74	0	NC*	Female	11.46	7	61
Total	2.46	1	NC*				
Lung and Bro	onchus		Al	ll Sites / Ty	pes		
Male	34.36	22	64 #-	Male	205.42	171	83 #-
Female	23.21	25	108	Female	185.86	183	98
Total	57.57	47	82	Total	391.28	354	90
1000	57.57	1 /	02	10111	371.20	55 1	70

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SHARON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

Exp Obs SIR Exp Obs SIR

Bladder, Urinary Melanoma of Skin

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	11.08	12	108	Male	6.07	4	NC*
Female	3.86	5	129	Female	4.80	7	146
Total	14.95	17	114	Total	10.86	11	101
Brain and Cent		<u>System</u>		<u>ultiple Mye</u>	<u>loma</u>		
Male	4.12	4	NC*	Male	2.03	3	NC*
Female	3.67	6	163	Female	1.75	1	NC*
Total	7.79	10	128	Total	3.78	4	NC*
Breast			<u>N</u>	on-Hodgkin	<u>'s Lymphoma</u>	<u>a</u>	
Male	0.61	0	NC*	Male	8.56	14	164
Female	66.79	83	124	Female	7.08	8	113
Total	67.40	83	123	Total	15.64	22	141
Cervix Uteri			<u>O</u> :	ral Cavity a	<u>nd Pharynx</u>		
				Male	8.26	6	73
Female	4.45	4	NC*	Female	3.35	3	NC*
				Total	11.61	9	77
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	29.44	25	85				
Female	25.38	25	98	Female	8.20	6	73
Total	54.82	50	91				
Esophagus			<u>Pa</u>	ancreas			
Male	4.03	5	124	Male	4.20	4	NC*
Female	1.26	1	NC*	Female	4.04	5	124
Total	5.30	6	113	Total	8.24	9	109
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>			
Male	1.85	5	271	Male	65.17	76	117
Female	1.48	1	NC*				
Total	3.32	6	180				
Kidney and Re				<u>omach</u>			
Male	6.91	12	174	Male	4.90	3	NC*
Female	3.84	3	NC*	Female	2.78	3	NC*
Total	10.75	15	140	Total	7.68	6	78
Larynx				estis_	,,,,,	-	, -
Male	4.43	4	NC*	Male	2.62	5	191
Female	1.16	0	NC*				-, -
Total	5.59	4	NC*				
<u>Leukemia</u>	3.03	•		nyroid			
Male	4.66	7	150	Male	1.16	2	NC*
Female	3.34	3	NC*	Female	3.12	5	160
Total	8.00	10	125	Total	4.29	7	163
Liver and Intra					and Uterus,		103
Male	1.91	0	NC*	cii, coi pus	una Ciclus,	1100	
Female	0.79	0	NC*	Female	12.56	14	111
Total	2.70	0	NC*	1 Sindic	12.50	1-1	111
Lung and Bron		U		ll Sites / Tyı	nec		
Lung and Divil	LIIUS		<u>A</u> 1	u sites / Ty	<u>JC3</u>		

Male	37.71	30	80	Male	225.72	236	105
Female	24.84	19	76	Female	203.07	215	106
Total	62.55	49	78	Total	428.79	451	105

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SHEFFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary	_		$\underline{\mathbf{N}}$	Ielanoma of	<u>Skin</u>		
Male	2.55	1	NC*	Male	1.30	1	NC*
Female	0.77	1	NC*	Female	0.94	2	NC*
Total	3.32	2	NC*	Total	2.24	3	NC*
Brain and Centra	al Nervous	s System	$\underline{\mathbf{N}}$	<u>Iultiple Mye</u>	<u>loma</u>		
Male	0.87	2	NC*	Male	0.46	0	NC*
Female	0.72	0	NC*	Female	0.35	0	NC*
Total	1.59	2	NC*	Total	0.81	0	NC*
Breast	Non-Hodgkin's Lymphoma						
Male	0.14	0	NC*	Male	1.88	0	NC*
Female	13.05	11	84	Female	1.41	0	NC*
Total	13.18	11	83	Total	3.28	0	NC*
Cervix Uteri			<u>O</u>	ral Cavity ar	nd Pharynx		
				Male	1.75	4	NC*
Female	0.87	0	NC*	Female	0.66	0	NC*
				Total	2.41	4	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	6.79	10	147				
Female	5.07	9	177	Female	1.60	0	NC*
Total	11.86	19	160				
Esophagus			<u>P</u>	<u>ancreas</u>			

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	0.88	2	NC*	Male	0.95	2	NC*
Female	0.26	0	NC*	Female	0.81	0	NC*
Total	1.14	2	NC*	Total	1.75	2	NC*
Hodgkin's D	<u>isease</u>						
Male	0.38	0	NC*	Male	15.42	7	45 #-
Female	0.29	0	NC*				
Total	0.67	0	NC*				
Kidney and I	Renal Pelvis		<u>St</u>	<u>omach</u>			
Male	1.52	0	NC*	Male	1.11	1	NC*
Female	0.76	1	NC*	Female	0.55	0	NC*
Total	2.28	1	NC*	Total	1.67	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.96	2	NC*	Male	0.54	0	NC*
Female	0.23	0	NC*				
Total	1.19	2	NC*				
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>			
Male	1.02	0	NC*	Male	0.24	1	NC*
Female	0.66	0	NC*	Female	0.61	2	NC*
Total	1.67	0	NC*	Total	0.85	3	NC*
Liver and Int	<u>rahepatic Bile I</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.42	0	NC*				
Female	0.16	0	NC*	Female	2.46	2	NC*
Total	0.58	0	NC*				
Lung and Bro	onchus_		<u>A</u>]	ll Sites / Tyr	<u>oes</u>		
Male	8.53	4	NC*	Male	51.26	39	76
Female	4.94	0	NC*	Female	40.05	28	70
Total	13.47	4	NC*	Total	91.30	67	73 ~-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

SHELBURNE

Cancer Incidence by Sex, 1990 - 1995

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>		
Male	1.54	0	NC*	Male	0.79	3	NC*
Female	0.85	0	NC*	Female	0.80	0	NC*
Total	2.40	0	NC*	Total	1.60	3	NC*
Brain and Cent	tral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Myel</u>	<u>oma</u>		
Male	0.52	1	NC*	Male	0.28	0	NC*
Female	0.61	0	NC*	Female	0.36	1	NC*
Total	1.14	1	NC*	Total	0.64	1	NC*
Breast			<u>N</u>	on-Hodgkin's	s Lymphoma	<u>1</u>	
Male	0.08	0	NC*	Male	1.14	1	NC*
Female	11.59	16	138	Female	1.42	1	NC*
Total	11.67	16	137	Total	2.56	2	NC*
<u>Cervix Uteri</u>			<u>O</u>	ral Cavity an	d Pharynx		
				Male	1.04	0	NC*
Female	0.69	2	NC*	Female	0.61	0	NC*
				Total	1.65	0	NC*
Colon / Rectum	<u>L</u>			<u>vary</u>			
Male	4.07	4	NC*				
Female	5.84	6	103	Female	1.37	0	NC*
Total	9.91	10	101				
Esophagus			<u>Pa</u>	ancreas			
Male	0.52	0	NC*	Male	0.56	1	NC*
Female	0.29	0	NC*	Female	0.88	0	NC*
Total	0.81	0	NC*	Total	1.44	1	NC*
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.24	0	NC*	Male	8.88	10	113
Female	0.23	0	NC*				
Total	0.47	0	NC*				
Kidney and Re				omach_			
Male	0.89	0	NC*	Male	0.68	0	NC*
Female	0.70	0	NC*	Female	0.66	0	NC*
Total	1.59	0	NC*	Total	1.34	0	NC*
<u>Larynx</u>			_	<u>estis</u>			
Male	0.56	2	NC*	Male	0.35	0	NC*
Female	0.19	0	NC*				
Total	0.75	2	NC*				
<u>Leukemia</u>				<u>hyroid</u>			
Male	0.62	1	NC*	Male	0.15	0	NC*
Female	0.64	0	NC*	Female	0.47	1	NC*
Total	1.25	1	NC*	Total	0.62	1	NC*

Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>				
Male	0.25	0	NC*				
Female	0.16	0	NC*	Female	2.12	4	NC*
Total	0.41	0	NC*				
Lung and Bronchus			All Sites / Types				
Male	4.93	5	101	Male	30.24	31	103
Female	4.44	9	203	Female	37.93	48	127
Total	9.36	14	150	Total	68.18	79	116

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SHERBORN

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>v</u>	Melanoma of Skin						
Male	2.89	2	NC*	Male	1.61	1	NC*	
Female	0.91	1	NC*	Female	1.27	4	NC*	
Total	3.80	3	NC*	Total	2.87	5	174	
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>			
Male	1.07	1	NC*	Male	0.54	0	NC*	
Female	0.96	3	NC*	Female	0.43	0	NC*	
Total	2.04	4	NC*	Total	0.96	0	NC*	
Breast			<u>N</u>	on-Hodgkin's	s Lymphom	<u>a</u>		
Male	0.16	0	NC*	Male	2.21	2	NC*	
Female	17.83	27	151	Female	1.73	0	NC*	
Total	18.00	27	150	Total	3.94	2	NC*	
Cervix Uteri			<u>O</u> :	ral Cavity an	d Pharynx			
				Male	2.29	2	NC*	
Female	1.18	0	NC*	Female	0.88	0	NC*	
				Total	3.17	2	NC*	

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Colon / Rectur	<u>n</u>		9	<u>Ovary</u>			
Male	7.69	11	143				
Female	5.81	8	138	Female	2.21	1	NC*
Total	13.50	19	141				
Esophagus]	<u>Pancreas</u>			
Male	1.11	0	NC*	Male	1.12	1	NC*
Female	0.29	0	NC*	Female	0.96	1	NC*
Total	1.40	0	NC*	Total	2.08	2	NC*
Hodgkin's Dis	sease_		_	<u>Prostate</u>			
Male	0.43	1	NC*	Male	16.99	15	88
Female	0.37	0	NC*				
Total	0.80	1	NC*				
Kidney and R			_	Stomach_			
Male	1.87	1	NC*	Male	1.28	0	NC*
Female	0.99	1	NC*	Female	0.63	0	NC*
Total	2.86	2	NC*	Total	1.90	0	NC*
<u>Larynx</u>			-	<u> Festis</u>			
Male	1.23	1	NC*	Male	0.57	1	NC*
Female	0.32	0	NC*				
Total	1.56	1	NC*				
<u>Leukemia</u>			_	<u> Fhyroid</u>			
Male	1.20	2	NC*	Male	0.29	1	NC*
Female	0.82	4	NC*	Female	0.82	0	NC*
Total	2.02	6	297 #+	Total	1.11	1	NC*
Liver and Intr	_		_	<u>Uteri, Corpu</u>	s and Uter	us, NOS	
Male	0.51	0	NC*				
Female	0.19	0	NC*	Female	3.42	6	175
Total	0.70	0	NC*				
Lung and Bro			-	All Sites / Ty			
Male	10.17	5	49	Male	59.38	48	81
Female	6.53	6	92	Female	52.03	65	125
Total	16.71	11	66	Total	111.42	113	101

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SHIRLEY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>v</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	3.68	4	NC*	Male	2.27	0	NC*	
Female	1.19	3	NC*	Female	1.64	2	NC*	
Total	4.87	7	144	Total	3.91	2	NC*	
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	<u>ultiple Mye</u>	<u>loma</u>			
Male	1.61	2	NC*	Male	0.67	0	NC*	
Female	1.24	1	NC*	Female	0.54	0	NC*	
Total	2.85	3	NC*	Total	1.21	0	NC*	
Breast			<u>No</u>	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>		
Male	0.21	0	NC*	Male	3.28	5	152	
Female	21.43	10	47 #-	Female	2.28	0	NC*	
Total	21.64	10	46 ~-	Total	5.57	5	90	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	2.87	3	NC*	
Female	1.62	3	NC*	Female	1.06	0	NC*	
				Total	3.93	3	NC*	
Colon / Rectum	_		<u>O</u>	<u>vary</u>				
Male	9.79	13	133					
Female	7.80	6	77	Female	2.69	3	NC*	
Total	17.59	19	108					
Esophagus				ancreas				
Male	1.33	3	NC*	Male	1.42	4	NC*	
Female	0.39	0	NC*	Female	1.25	0	NC*	
Total	1.72	3	NC*	Total	2.67	4	NC*	
Hodgkin's Dise	ease_		<u>Pr</u>	<u>rostate</u>				
Male	0.91	5	548 ~+	Male	21.40	19	89	
Female	0.59	1	NC*					
Total	1.50	6	399 #+					
Kidney and Re				<u>omach</u>				
Male	2.37	1	NC*	Male	1.65	1	NC*	
Female	1.23	2	NC*	Female	0.85	3	NC*	
Total	3.60	3	NC*	Total	2.50	4	NC*	
<u>Larynx</u>				<u>estis</u>				
Male	1.47	2	NC*	Male	1.52	0	NC*	
Female	0.36	0	NC*					

Total	1.83	2	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	1.70	1	NC*	Male	0.52	0	NC*
Female	1.12	1	NC*	Female	1.18	1	NC*
Total	2.82	2	NC*	Total	1.70	1	NC*
Liver and Int	rahepatic Bile	<u>Ducts</u>	<u>U</u> 1	t <mark>eri, Corpus</mark>	and Uterus	, NOS	
Male	0.66	0	NC*				
Female	0.25	0	NC*	Female	3.94	5	127
Total	0.91	0	NC*				
Lung and Bro	<u>nchus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	12.50	16	128	Male	77.74	87	112
Female	7.81	11	141	Female	65.08	56	86
Total	20.31	27	133	Total	142.81	143	100

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

SHREWSBURY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	ry		<u>M</u>	elanoma of	<u>Skin</u>				
Male	20.48	22	107	Male	10.68	12	112		
Female	7.22	7	97	Female	8.47	9	106		
Total	27.70	29	105	Total	19.15	21	110		
Brain and Cen	tral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	ultiple Mye	<u>loma</u>				
Male	7.09	8	113	Male	3.71	5	135		
Female	6.47	8	124	Female	3.25	3	NC*		
Total	13.56	16	118	Total	6.96	8	115		
Breast			Non-Hodgkin's Lymphoma						
Male	1.09	1	NC*	Male	15.34	18	117		
Female	119.41	119	100	Female	13.04	16	123		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	120.51	120	100	Total	28.38	34	120
Cervix Uteri					nd Pharynx		
				Male	14.15	10	71
Female	7.76	6	77	Female	6.02	7	116
				Total	20.17	17	84
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	54.42	44	81				
Female	47.94	45	94	Female	14.52	12	83
Total	102.36	89	87				
Esophagus				ncreas			
Male	7.08	5	71	Male	7.59	7	92
Female	2.39	3	NC*	Female	7.62	4	NC*
Total	9.47	8	84	Total	15.21	11	72
Hodgkin's Dis				<u>costate</u>			
Male	3.24	3	NC*	Male	122.21	126	103
Female	2.56	1	NC*				
Total	5.81	4	NC*				
Kidney and Re	<u>.</u>			<u>omach</u>			
Male	12.13	8	66	Male	9.00	10	111
Female	6.99	5	72	Female	5.22	2	NC*
Total	19.13	13	68	Total	14.22	12	84
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	7.68	9	117	Male	4.76	13	273 ~+
Female	2.05	3	NC*				
Total	9.73	12	123				
<u>Leukemia</u>				<u>ıyroid</u>			
Male	8.20	4	NC*	Male	2.03	5	247
Female	5.97	5	84	Female	5.41	4	NC*
Total	14.17	9	64	Total	7.44	9	121
Liver and Intra	_			<u>teri, Corpus</u>	s and Uterus.	NOS	
Male	3.40	3	NC*				
Female	1.47	2	NC*	Female	22.47	25	111
Total	4.87	5	103				
Lung and Bron				ll Sites / Ty			
Male	67.84	48	71 #-	Male	410.96	399	97
Female	45.69	43	94	Female	368.57	347	94
Total	113.53	91	80 #-	Total	779.53	746	96

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SHUTESBURY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR
Bladder, Urinary			<u>M</u>	<u>lelanoma of S</u>	<u>Skin</u>		
Male	0.92	0	NC*	Male	0.58	0	NC*
Female	0.26	1	NC*	Female	0.45	1	NC*
Total	1.18	1	NC*	Total	1.02	1	NC*
Brain and Centra	l Nervous	<u>System</u>	<u>M</u>	<u>lultiple Myel</u>	<u>oma</u>		
Male	0.41	1	NC*	Male	0.17	0	NC*
Female	0.32	1	NC*	Female	0.12	0	NC*
Total	0.74	2	NC*	Total	0.29	0	NC*
Breast			<u>N</u> o	on-Hodgkin's	s Lymphoma	<u>ı</u>	
Male	0.05	0	NC*	Male	0.83	0	NC*
Female	5.36	4	NC*	Female	0.54	1	NC*
Total	5.42	4	NC*	Total	1.37	1	NC*
Cervix Uteri			<u>O</u> :	ral Cavity an	<u>d Pharynx</u>		
				Male	0.75	0	NC*
Female	0.47	0	NC*	Female	0.26	0	NC*
				Total	1.01	0	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	2.44	0	NC*				
Female	1.68	0	NC*	Female	0.70	1	NC*
Total	4.12	0	NC*				
Esophagus				ancreas			
Male	0.34	0	NC*	Male	0.36	0	NC*
Female	0.08	0	NC*	Female	0.27	0	NC*
Total	0.43	0	NC*	Total	0.62	0	NC*
Hodgkin's Diseas	<u>se</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.23	0	NC*	Male	5.17	3	NC*
Female	0.18	0	NC*				
Total	0.41	0	NC*				
Kidney and Rena	l Pelvis		<u>St</u>	<u>omach</u>			
Male	0.61	0	NC*	Male	0.42	0	NC*
Female	0.29	0	NC*	Female	0.19	1	NC*

Total	0.90	0	NC*	Total	0.60	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.38	0	NC*	Male	0.36	0	NC*
Female	0.09	0	NC*				
Total	0.47	0	NC*				
Leukemia			<u>Tl</u>	<u>iyroid</u>			
Male	0.44	0	NC*	Male	0.13	0	NC*
Female	0.28	1	NC*	Female	0.35	0	NC*
Total	0.72	1	NC*	Total	0.48	0	NC*
Liver and Int	rahepatic Bile	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	0.17	0	NC*				
Female	0.06	0	NC*	Female	0.95	0	NC*
Total	0.22	0	NC*				
Lung and Bro	onchus_		<u>A</u>]	ll Sites / Tyr	<u>oes</u>		
Male	3.14	1	NC*	Male	19.39	5	26 ^-
Female	1.78	2	NC*	Female	15.74	16	102
Total	4.92	3	NC*	Total	35.13	21	60 #-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

SOMERSET

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Uri	<u>nary</u>	Melanoma of Skin							
Male	16.90	21	124	Male	8.27	9	109		
Female	6.55	4	NC*	Female	6.71	5	75		
Total	23.45	25	107	Total	14.98	14	93		
Brain and Co	entral Nervous	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>				
Male	5.35	3	NC*	Male	3.04	5	164		
Female	5.21	11	211 #+	Female	2.92	3	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	10.56	14	133	Total	5.96	8	134
Breast			<u>N</u> e	on-Hodgkin	's Lymphom	<u>1a</u>	
Male	0.89	0	NC*	Male	11.81	7	59
Female	100.06	94	94	Female	11.28	8	71
Total	100.95	94	93	Total	23.10	15	65
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	11.30	5	44
Female	5.74	4	NC*	Female	5.16	6	116
				Total	16.46	11	67
Colon / Rectur	<u>n</u>		$\overline{\mathbf{O}}$	<u>vary</u>			
Male	44.97	37	82				
Female	43.86	50	114	Female	11.87	17	143
Total	88.83	87	98				
Esophagus			<u>Pa</u>	ancreas			
Male	5.81	6	103	Male	6.25	3	NC*
Female	2.19	1	NC*	Female	6.90	5	72
Total	8.00	7	87	Total	13.15	8	61
Hodgkin's Dis	sease_		<u>Pr</u>	<u>costate</u>			
Male	2.12	6	283 #+	Male	103.44	101	98
Female	1.75	1	NC*				
Total	3.87	7	181				
Kidney and R	<u>enal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	9.82	11	112	Male	7.35	6	82
Female	6.00	1	NC*	Female	4.79	12	251 ~+
Total	15.82	12	76	Total	12.14	18	148
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	6.31	5	79	Male	2.78	4	NC*
Female	1.74	0	NC*				
Total	8.06	5	62				
<u>Leukemia</u>				<u>iyroid</u>			
Male	6.41	5	78	Male	1.42	0	NC*
Female	4.97	9	181	Female	3.87	4	NC*
Total	11.37	14	123	Total	5.29	4	NC*
Liver and Intr	_			<u>teri, Corpus</u>	and Uterus	, NOS	
Male	2.77	2	NC*				
Female	1.29	1	NC*	Female	19.09	20	105
Total	4.06	3	NC*				
Lung and Bro				ll Sites / Ty		.	a =
Male	56.35	60	106	Male	335.99	319	95
Female	39.64	34	86	Female	314.90	310	98
Total	95.99	94	98	Total	650.89	629	97

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SOMERVILLE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>				
Male	45.78	43	94	Male	26.60	19	71		
Female	19.97	19	95	Female	25.19	13	52 #-		
Total	65.75	62	94	Total	51.79	32	62 ~-		
Brain and Cen	<u>tral Nervous</u>	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>				
Male	18.13	9	50 #-	Male	8.27	7	85		
Female	18.32	21	115	Female	8.84	13	147		
Total	36.44	30	82	Total	17.11	20	117		
Breast			Non-Hodgkin's Lymphoma						
Male	2.49	2	NC*	Male	39.01	34	87		
Female	328.96	286	87 #-	Female	37.05	30	81		
Total	331.45	288	87 #-	Total	76.07	64	84		
<u>Cervix Uteri</u>			Oral Cavity and Pharynx						
				Male	32.56	25	77		
Female	24.75	24	97	Female	16.41	14	85		
				Total	48.97	39	80		
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>					
Male	121.46	135	111						
Female	133.89	121	90	Female	40.75	31	76		
Total	255.36	256	100						
Esophagus			<u>Pa</u>	ancreas					
Male	15.54	17	109	Male	17.02	21	123		
Female	6.58	2	NC*	Female	20.97	21	100		
Total	22.12	19	86	Total	37.99	42	111		
Hodgkin's Dis	<u>ease</u>			<u>rostate</u>					
Male	10.47	2	NC*	Male	265.30	223	84 ~-		

Female	8.90	11	124					
Total	19.36	13	67					
Kidney and R	<u>enal Pelvis</u>			Stomach_				
Male	27.53	30	109	Male	20.44	26	127	
Female	18.96	24	127	Female	14.78	21	142	
Total	46.49	54	116	Total	35.22	47	133	
<u>Larynx</u>			<u>Testis</u>					
Male	16.83	33	196 ^+	Male	17.99	22	122	
Female	5.24	16	306 ^+					
Total	22.06	49	222 ^+					
Leukemia				<u>Thyroid</u>				
Male	19.68	16	81	Male	6.01	9	150	
Female	17.01	10	59	Female	17.81	17	95	
Total	36.69	26	71	Total	23.81	26	109	
Liver and Intr	ahepatic Bil	e Ducts		<u>Uteri, Corpu</u>	s and Uteru	is, NOS		
Male	7.72	9	117					
Female	4.06	5	123	Female	59.46	56	94	
Total	11.78	14	119					
Lung and Bro	<u>nchus</u>		i	All Sites / Ty	<u>pes</u>			
Male	148.57	160	108	Male	937.70	932	99	
Female	121.33	126	104	Female	1024.10	947	92 #-	
Total	269.90	286	106	Total	1961.81	1879	96	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SOUTH HADLEY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinaı	<u>ry</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	13.92	19	136	Male	6.78	9	133

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	5.48	7	128	Female	6.18	4	NC*
Total	19.41	26	134	Total	12.96	13	100
Brain and Cent	ral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>eloma</u>		
Male	4.43	9	203	Male	2.51	2	NC*
Female	4.76	5	105	Female	2.43	2	NC*
Total	9.19	14	152	Total	4.94	4	NC*
<u>Breast</u>			<u>N</u>	<u>on-Hodgkin</u>	<u>'s Lymphom</u>	<u>a</u>	
Male	0.73	0	NC*	Male	9.82	10	102
Female	85.84	71	83	Female	9.81	3	NC*
Total	86.57	71	82	Total	19.63	13	66
<u>Cervix Uteri</u>			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	9.03	9	100
Female	5.70	5	88	Female	4.38	5	114
				Total	13.40	14	104
Colon / Rectum	<u>L</u>		\mathbf{O}	<u>vary</u>			
Male	37.04	41	111				
Female	36.82	34	92	Female	10.44	13	125
Total	73.86	75	102				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	4.68	5	107	Male	5.09	10	197
Female	1.83	1	NC*	Female	5.77	5	87
Total	6.50	6	92	Total	10.86	15	138
Hodgkin's Dise	ease		<u>P</u> 1	<u>rostate</u>			
Male	1.87	3	NC*	Male	84.77	80	94
Female	1.99	1	NC*				
Total	3.86	4	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	tomach_			
Male	7.96	10	126	Male	6.06	7	116
Female	5.12	6	117	Female	4.04	3	NC*
Total	13.08	16	122	Total	10.09	10	99
<u>Larynx</u>			\mathbf{T}	<u>estis</u>			
Male	5.02	6	119	Male	2.56	5	195
Female	1.43	1	NC*				
Total	6.45	7	109				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	5.32	4	NC*	Male	1.20	0	NC*
Female	4.54	5	110	Female	4.03	5	124
Total	9.86	9	91	Total	5.23	5	96
Liver and Intra	hepatic Bile	<u>Ducts</u>	<u>U</u>	teri, Corpus	and Uterus,	NOS	
Male	2.25	4	NC*				
Female	1.11	1	NC*	Female	15.93	9	56
Total	3.36	5	149				
Lung and Bron	<u>chus</u>		<u>A</u>	ll Sites / Ty	<u>pes</u>		
Male	45.68	35	77	Male	275.50	281	102

Female	33.05	27	82	Female	270.82	232	86 #-
Total	78.72	62	79	Total	546.32	513	94

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SOUTHAMPTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>y</u>		<u>M</u>	elanoma of S	<u>Skin</u>			
Male	3.04	8	263 #+	Male	1.76	2	NC*	
Female	0.99	0	NC*	Female	1.32	0	NC*	
Total	4.03	8	198	Total	3.07	2	NC*	
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>			
Male	1.22	0	NC*	Male	0.56	0	NC*	
Female	1.01	1	NC*	Female	0.45	0	NC*	
Total	2.22	1	NC*	Total	1.01	0	NC*	
Breast		Non-Hodgkin's Lymphoma						
Male	0.17	0	NC*	Male	2.49	1	NC*	
Female	17.95	11	61	Female	1.87	2	NC*	
Total	18.12	11	61	Total	4.35	3	NC*	
Cervix Uteri			<u>O</u> :	ral Cavity an	d Pharynx			
				Male	2.37	1	NC*	
Female	1.26	0	NC*	Female	0.90	1	NC*	
				Total	3.26	2	NC*	
Colon / Rectum	_		<u>O</u>	<u>vary</u>				
Male	8.10	10	123					
Female	6.42	5	78	Female	2.23	2	NC*	
Total	14.52	15	103					
Esophagus			<u>Pa</u>	ancreas				
Male	1.13	0	NC*	Male	1.17	1	NC*	

^{* =} SIR and statistical significance not calculated when Obs < 5

Female	0.32	1	NC*	Female	1.04	4	NC*
Total	1.45	1	NC*	Total	2.21	5	226
Hodgkin's Dise	ease		<u>P</u> 1	<u>rostate</u>			
Male	0.59	0	NC*	Male	17.88	18	101
Female	0.43	0	NC*				
Total	1.02	0	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	1.96	0	NC*	Male	1.35	1	NC*
Female	1.03	4	NC*	Female	0.69	0	NC*
Total	2.99	4	NC*	Total	2.04	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.25	1	NC*	Male	0.88	2	NC*
Female	0.31	0	NC*				
Total	1.57	1	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	1.34	1	NC*	Male	0.36	1	NC*
Female	0.89	0	NC*	Female	0.89	0	NC*
Total	2.23	1	NC*	Total	1.25	1	NC*
Liver and Intra	hepatic Bile I	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS	
Male	0.54	0	NC*				
Female	0.21	0	NC*	Female	3.39	6	177
Total	0.75	0	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	10.54	8	76	Male	63.26	60	95
Female	6.71	6	89	Female	54.09	47	87
Total	17.26	14	81	Total	117.36	107	91

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SOUTHBOROUGH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinary	<u>v</u> _		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>			
Male	4.36	4	NC*	Male	2.59	5	193	
Female	1.51	1	NC*	Female	2.08	4	NC*	
Total	5.87	5	85	Total	4.67	9	193	
Brain and Centr	al Nervous	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>			
Male	1.80	3	NC*	Male	0.81	4	NC*	
Female	1.56	0	NC*	Female	0.70	1	NC*	
Total	3.36	3	NC*	Total	1.51	5	331 #+	
Breast				<u>on-Hodgkin'</u>	s Lymphoma	<u>ı</u>		
Male	0.25	0	NC*	Male	3.62	0	NC*	
Female	28.41	27	95	Female	2.87	2	NC*	
Total	28.65	27	94	Total	6.49	2	NC*	
<u>Cervix Uteri</u>			Oral Cavity and Pharynx					
				Male	3.55	3	NC*	
Female	1.98	1	NC*	Female	1.40	0	NC*	
				Total	4.94	3	NC*	
Colon / Rectum			<u>O</u>	<u>vary</u>				
Male	11.63	16	138					
Female	9.77	8	82	Female	3.53	3	NC*	
Total	21.40	24	112					
Esophagus			<u>Pa</u>	ancreas				
Male	1.68	1	NC*	Male	1.70	6	352 #+	
Female	0.49	2	NC*	Female	1.59	2	NC*	
Total	2.16	3	NC*	Total	3.29	8	243 #+	
Hodgkin's Dise	<u>ase</u>		<u>P</u> 1	<u>rostate</u>				
Male	0.85	2	NC*	Male	25.46	21	82	
Female	0.66	1	NC*					
Total	1.50	3	NC*					
Kidney and Ren	<u>al Pelvis</u>		<u>St</u>	omach_				
Male	2.91	5	172	Male	1.94	5	258	
Female	1.59	4	NC*	Female	1.06	1	NC*	
Total	4.50	9	200	Total	3.00	6	200	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	1.87	0	NC*	Male	1.26	2	NC*	
Female	0.50	0	NC*					
Total	2.36	0	NC*					
Leukemia				<u>hyroid</u>				
Male	1.95	0	NC*	Male	0.53	1	NC*	
Female	1.36	4	NC*	Female	1.40	3	NC*	
Total	3.31	4	NC*	Total	1.93	4	NC*	
Liver and Intral	_	<u>Ducts</u>		<u>teri, Corpus</u>	and Uterus,	NOS_		
Male	0.79	0	NC*					

Female	0.32	1	NC*	Female	5.35	9	168
Total	1.11	1	NC*				
Lung and Bron	<u>nchus</u>		<u>A</u>]	ll Sites / Ty	pes		
Male	15.43	15	97	Male	91.60	100	109
Female	10.36	4	NC*	Female	84.26	82	97
Total	25.79	19	74	Total	175.86	182	103

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SOUTHBRIDGE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urinaı	<u>y</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>			
Male	14.10	15	106	Male	6.88	6	87	
Female	6.61	9	136	Female	6.34	4	NC*	
Total	20.71	24	116	Total	13.22	10	76	
Brain and Cent	ral Nervous	<u>System</u>	Multiple Myeloma					
Male	4.57	5	109	Male	2.51	6	239	
Female	4.92	3	NC*	Female	2.85	1	NC*	
Total	9.50	8	84	Total	5.36	7	131	
Breast			Non-Hodgkin's Lymphoma					
Male	0.73	2	NC*	Male	10.10	9	89	
Female	91.61	102	111	Female	11.15	13	117	
Total	92.35	104	113	Total	21.26	22	104	
Cervix Uteri			<u>O</u>	ral Cavity aı	nd Pharynx			
				Male	8.80	14	159	
Female	5.44	7	129	Female	4.81	3	NC*	
				Total	13.60	17	125	
Colon / Rectum	<u> </u>		<u>o</u>	<u>vary</u>				
Male	37.22	43	116					

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	45.21	43	95	Female	10.85	10	92
Total	82.44	86	104				
Esophagus			<u>Pa</u>	ancreas			
Male	4.55	3	NC*	Male	5.00	3	NC*
Female	2.23	0	NC*	Female	6.88	4	NC*
Total	6.78	3	NC*	Total	11.87	7	59
Hodgkin's Dis	ease		<u>Pr</u>	<u>rostate</u>			
Male	2.13	0	NC*	Male	82.10	74	90
Female	1.83	2	NC*				
Total	3.96	2	NC*				
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	7.74	5	65	Male	6.20	7	113
Female	5.59	4	NC*	Female	5.06	4	NC*
Total	13.33	9	68	Total	11.25	11	98
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	4.80	6	125	Male	3.05	5	164
Female	1.48	0	NC*				
Total	6.28	6	96				
<u>Leukemia</u>			<u>Tl</u>	<u>hyroid</u>			
Male	5.53	5	90	Male	1.27	3	NC*
Female	5.06	6	118	Female	3.78	2	NC*
Total	10.60	11	104	Total	5.04	5	99
Liver and Intr	<u>ahepatic Bile</u>	Ducts	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus	s, NOS	
Male	2.21	2	NC*				
Female	1.28	1	NC*	Female	16.85	17	101
Total	3.49	3	NC*				
Lung and Bron	<u>ichus</u>		$\underline{\mathbf{A}}$	ll Sites / Ty	pes		
Male	43.88	51	116	Male	272.76	277	102
Female	35.49	24	68	Female	298.84	287	96
Total	79.37	75	94	Total	571.60	564	99

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SOUTHWICK

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR	
Bladder, Urina	ry		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	5.10	4	NC*	Male	2.89	3	NC*	
Female	1.62	0	NC*	Female	2.21	3	NC*	
Total	6.72	4	NC*	Total	5.10	6	118	
Brain and Cen	tral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	2.02	3	NC*	Male	0.93	2	NC*	
Female	1.69	0	NC*	Female	0.74	1	NC*	
Total	3.71	3	NC*	Total	1.67	3	NC*	
Breast			Non-Hodgkin's Lymphoma					
Male	0.28	0	NC*	Male	4.13	1	NC*	
Female	29.74	19	64 #-	Female	3.09	1	NC*	
Total	30.02	19	63 #-	Total	7.23	2	NC*	
<u>Cervix Uteri</u>			<u>O</u> :	ral Cavity a	nd Pharynx			
				Male	3.83	1	NC*	
Female	2.13	2	NC*	Female	1.47	2	NC*	
				Total	5.30	3	NC*	
Colon / Rectun	<u>n</u>		<u>O</u>	<u>vary</u>				
Male	13.54	11	81					
Female	10.55	10	95	Female	3.71	3	NC*	
Total	24.09	21	87					
Esophagus			<u>Pa</u>	ancreas				
Male	1.84	1	NC*	Male	1.93	1	NC*	
Female	0.52	2	NC*	Female	1.71	2	NC*	
Total	2.36	3	NC*	Total	3.64	3	NC*	
Hodgkin's Dis	ease		<u>P1</u>	<u>rostate</u>				
Male	1.00	0	NC*	Male	29.83	17	57 #-	
Female	0.75	1	NC*					
Total	1.75	1	NC*					
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>				
Male	3.20	2	NC*	Male	2.27	2	NC*	
Female	1.70	1	NC*	Female	1.14	1	NC*	
Total	4.90	3	NC*	Total	3.41	3	NC*	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				
Male	2.03	1	NC*	Male	1.50	1	NC*	
Female	0.51	0	NC*					
Total	2.54	1	NC*					
Leukemia			<u>Tl</u>	<u>nyroid</u>				

Male	2.24	0	NC*	Male	0.59	0	NC*	
Female	1.50	2	NC*	Female	1.52	1	NC*	
Total	3.75	2	NC*	Total	2.12	1	NC*	
Liver and Intra	hepatic Bile I	<u>Ducts</u>	<u>Uteri, Corpus and Uterus, NOS</u>					
Male	0.89	1	NC*					
Female	0.34	0	NC*	Female	5.56	11	198	
Total	1.23	1	NC*					
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty	pes			
Male	17.24	15	87	Male	104.92	73	70 ~-	
Female	11.00	11	100	Female	89.49	77	86	
Total	28.24	26	92	Total	194.41	150	77 ~-	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SPENCER

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	ry		<u>M</u>	elanoma of	<u>Skin</u>		
Male	8.35	10	120	Male	4.50	5	111
Female	2.79	2	NC*	Female	3.50	0	NC*
Total	11.14	12	108	Total	7.99	5	63
Brain and Cen	tral Nervous S	<u>Multiple Myeloma</u>					
Male	3.05	3	NC*	Male	1.52	1	NC*
Female	2.68	1	NC*	Female	1.26	0	NC*
Total	5.74	4	NC*	Total	2.78	1	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>a</u> _	
Male	0.45	0	NC*	Male	6.45	7	108
Female	47.66	48	101	Female	5.18	8	154
Total	48.11	48	100	Total	11.64	15	129
<u>Cervix Uteri</u>			<u>O</u> :	ral Cavity aı	nd Pharynx		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Male	5.92	7	118
Female	3.32	1	NC*	Female	2.39	0	NC*
				Total	8.31	7	84
Colon / Rectun	<u>n</u> _		<u>O</u>	<u>vary</u>			
Male	22.13	24	108				
Female	18.48	20	108	Female	5.88	6	102
Total	40.61	44	108				
Esophagus			<u>Pa</u>	ancreas			
Male	2.92	2	NC*	Male	3.10	5	161
Female	0.92	3	NC*	Female	2.95	2	NC*
Total	3.84	5	130	Total	6.05	7	116
Hodgkin's Dis	sease		<u>Pı</u>	<u>rostate</u>			
Male	1.45	0	NC*	Male	48.77	39	80
Female	1.17	1	NC*				
Total	2.62	1	NC*				
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	5.02	3	NC*	Male	3.69	2	NC*
Female	2.79	4	NC*	Female	2.01	3	NC*
Total	7.81	7	90	Total	5.70	5	88
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	3.17	1	NC*	Male	2.15	3	NC*
Female	0.81	1	NC*				
Total	3.98	2	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>hyroid</u>			
Male	3.49	0	NC*	Male	0.88	0	NC*
Female	2.45	1	NC*	Female	2.36	3	NC*
Total	5.94	1	NC*	Total	3.25	3	NC*
Liver and Intr	ahepatic Bile	Ducts		<u>teri, Corpus</u>	and Uterus,	NOS	
Male	1.40	0	NC*				
Female	0.58	1	NC*	Female	8.89	10	112
Total	1.98	1	NC*				
Lung and Bron				ll Sites / Ty			
Male	27.57	30	109	Male	168.08	149	89
Female	18.06	20	111	Female	146.65	151	103
Total	45.63	50	110	Total	314.72	300	95

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

SPRINGFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		1	Melanoma of	<u>Skin</u>		
Male	102.69	76	74 ~-	Male	53.06	35	66 #-
Female	42.89	45	105	Female	48.90	27	55 ^-
Total	145.58	121	83 #-	Total	101.96	62	61 ^-
Brain and Cen	<u>tral Nervou</u>	s System	1	Multiple My	<u>eloma</u>		
Male	36.83	25	68	Male	18.45	18	98
Female	38.03	32	84	Female	19.00	20	105
Total	74.86	57	76 #-	Total	37.45	38	101
Breast			1	Non-Hodgkir	<u>ı's Lymphon</u>	<u>1a</u>	
Male	5.43	10	184	Male	77.91	71	91
Female	675.64	597	88 ~-	Female	77.01	69	90
Total	681.07	607	89 ~-	Total	154.92	140	90
<u>Cervix Uteri</u>			9	Oral Cavity a	nd Pharynx		
				Male	68.10	73	107
Female	45.17	46	102	Female	34.44	39	113
				Total	102.54	112	109
Colon / Rectum	<u>1</u>		9	<u>Ovary</u>			
Male	272.33	282	104				
Female	287.76	278	97	Female	82.48	65	79
Total	560.09	560	100				
Esophagus			<u>]</u>	<u>Pancreas</u>			
Male	34.30	49	143 #+	Male	37.45	47	125
Female	14.25	9	63	Female	45.09	37	82
Total	48.56	58	119	Total	82.54	84	102
Hodgkin's Dis	<u>ease</u>]	<u>Prostate</u>			
Male	18.03	8	44 #-	Male	609.28	547	90 #-
Female	16.07	12	75				
Total	34.10	20	59 #-				
Kidney and Re	<u>enal Pelvis</u>		5	Stomach_			
Male	59.48	50	84	Male	45.17	66	146 ~+
Female	40.35	32	79	Female	31.61	36	114
Total	99.83	82	82	Total	76.78	102	133 ~+
<u>Larynx</u>			_	<u> Festis</u>			

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	36.84	34	92	Male	26.48	16	60 #-
Female	11.21	7	62				
Total	48.05	41	85				
<u>Leukemia</u>			<u>Tl</u>	<u> </u>			
Male	43.09	28	65 #-	Male	10.42	9	86
Female	36.37	23	63 #-	Female	32.12	25	78
Total	79.46	51	64 ^-	Total	42.55	34	80
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri, C</u>					and Uterus,	NOS	
Male	16.84	17	101				
Male Female	16.84 8.73	17 10	101 115	Female	125.18	129	103
				Female	125.18	129	103
Female	8.73 25.57	10	115 106	Female		129	103
Female Total	8.73 25.57	10	115 106			129 1963	103 96
Female Total Lung and Bron	8.73 25.57 nchus	10 27	115 106 <u>A</u> l	ll Sites / Ty	<u>pes</u>		
Female Total Lung and Bron Male	8.73 25.57 nchus 331.50	10 27 342	115 106 <u>A</u> 1 103	l <mark>l Sites / Ty</mark> Male	pes 2051.18	1963	96

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

STERLING

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR		
Bladder, Urinar	<u>v</u>	Melanoma of Skin							
Male	4.45	3	NC*	Male	2.49	1	NC*		
Female	1.34	2	NC*	Female	1.85	0	NC*		
Total	5.79	5	86	Total	4.34	1	NC*		
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Myel</u>	<u>oma</u>				
Male	1.72	2	NC*	Male	0.81	2	NC*		
Female	1.41	1	NC*	Female	0.61	0	NC*		
Total	3.12	3	NC*	Total	1.42	2	NC*		
Breast			N	on-Hodgkin's	s Lymphoma	a			

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	0.24	1	NC*	Male	3.53	4	NC*
Female	24.55	24	98	Female	2.56	1	NC*
Total	24.33	24 25	101	Total	6.10	5	82
	24.60	23				3	82
<u>Cervix Uteri</u>			<u>U</u>	-	nd Pharynx	2	NICH
Б 1	1.00	2	Mode	Male	3.35	2	NC*
Female	1.80	2	NC*	Female	1.22	2	NC*
				Total	4.57	4	NC*
Colon / Rectun	_			<u>vary</u>			
Male	11.82	7	59				
Female	8.69	9	104	Female	3.08	4	NC*
Total	20.51	16	78				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	1.62	2	NC*	Male	1.69	1	NC*
Female	0.43	0	NC*	Female	1.40	2	NC*
Total	2.05	2	NC*	Total	3.09	3	NC*
Hodgkin's Dis	<u>ease</u>		<u>Pr</u>	<u>costate</u>			
Male	0.81	1	NC*	Male	26.17	22	84
Female	0.64	0	NC*				
Total	1.45	1	NC*				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	2.79	1	NC*	Male	1.97	0	NC*
Female	1.40	4	NC*	Female	0.94	0	NC*
Total	4.20	5	119	Total	2.91	0	NC*
<u>Larynx</u>		-		estis_			
Male	1.78	0	NC*	Male	1.19	0	NC*
Female	0.42	0	NC*				
Total	2.21	0	NC*				
Leukemia		_		nyroid			
Male	1.92	1	NC*	Male	0.50	1	NC*
Female	1.25	0	NC*	Female	1.29	2	NC*
Total	3.17	1	NC*	Total	1.79	3	NC*
Liver and Intra					and Uterus,		110
Male Male	0.77	1	NC*	ceri, corpus	tira eterus,	1100	
Female	0.28	1	NC*	Female	4.58	7	153
Total	1.06	2	NC*	1 Ciliaic	7.50	,	133
Lung and Bron		2		ll Sites / Ty	nes		
Male	15.16	9	59	Male	91.34	68	74 #-
Female	9.01	8	89	Female	73.95	72	74 #- 97
Total			70				85 #-
1 Otal	24.17	17	70	Total	165.29	140	o3 #-

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

STOCKBRIDGE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>y</u>		<u>M</u>	elanoma of	<u>Skin</u>		
Male	2.25	2	NC*	Male	1.07	0	NC*
Female	0.74	1	NC*	Female	0.84	0	NC*
Total	3.00	3	NC*	Total	1.91	0	NC*
Brain and Cent	ral Nervous	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>		
Male	0.69	1	NC*	Male	0.41	0	NC*
Female	0.64	0	NC*	Female	0.34	0	NC*
Total	1.33	1	NC*	Total	0.74	0	NC*
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>	
Male	0.12	0	NC*	Male	1.55	0	NC*
Female	12.20	9	74	Female	1.32	0	NC*
Total	12.31	9	73	Total	2.88	0	NC*
<u>Cervix Uteri</u>			<u>O</u> 1	<u>ral Cavity ar</u>	<u>nd Pharynx</u>		
				Male	1.43	1	NC*
Female	0.75	0	NC*	Female	0.62	0	NC*
				Total	2.05	1	NC*
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	6.00	0	NC*				
Female	4.93	9	183	Female	1.47	1	NC*
Total	10.93	9	82				
Esophagus			<u>Pa</u>	ancreas			
Male	0.75	0	NC*	Male	0.82	0	NC*
Female	0.25	0	NC*	Female	0.79	0	NC*
Total	1.00	0	NC*	Total	1.61	0	NC*
Hodgkin's Dise	<u>ease</u>		<u>P1</u>	<u>rostate</u>			
Male	0.28	0	NC*	Male	13.86	6	43 #-
Female	0.23	0	NC*				
Total	0.51	0	NC*				

Kidney and Ro	Stomach						
Male	1.27	2	NC*	Male	0.97	0	NC*
Female	0.72	0	NC*	Female	0.53	1	NC*
Total	1.99	2	NC*	Total	1.51	1	NC*
<u>Larynx</u>			<u>T</u>				
Male	0.80	2	NC*	Male	0.37	0	NC*
Female	0.21	0	NC*				
Total	1.02	2	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>ıyroid</u>			
Male	0.84	1	NC*	Male	0.18	0	NC*
Female	0.58	1	NC*	Female	0.51	0	NC*
Total	1.43	2	NC*	Total	0.70	0	NC*
Liver and Intr	<u>ahepatic Bile D</u>	<u>Oucts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	0.36	0	NC*				
Female	0.15	0	NC*	Female	2.33	3	NC*
Total	0.51	0	NC*				
Lung and Bron	<u>nchus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>		
Male	7.40	2	NC*	Male	44.42	19	43 ^-
Female	4.75	1	NC*	Female	37.59	28	74
Total	12.15	3	NC*	Total	82.01	47	57 ^-

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

STONEHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinaı	<u>ry</u>	Melanoma of Skin							
Male	18.47	12	65	Male	9.29	8	86		
Female	7.74	5	65	Female	8.06	10	124		
Total	26.21	17	65	Total	17.35	18	104		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Brain and Central Nervous System Multiple					<u>eloma</u>		
Male	6.03	5	83	Male	3.32	2	NC*
Female	6.17	4	NC*	Female	3.41	4	NC*
Total	12.20	9	74	Total	6.73	6	89
Breast			<u>N</u>	on-Hodgkin	's Lymphom	a_	
Male	0.98	0	NC*	Male	13.37	15	112
Female	116.77	123	105	Female	13.41	8	60
Total	117.74	123	104	Total	26.78	23	86
<u>Cervix Uteri</u>			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	12.26	12	98
Female	7.09	5	71	Female	6.01	2	NC*
				Total	18.26	14	77
Colon / Rectum	_			<u>vary</u>			
Male	48.95	58	118				
Female	52.16	68	130 #+	Female	13.94	20	143
Total	101.11	126	125 #+				
Esophagus				ancreas			
Male	6.24	6	96	Male	6.73	6	89
Female	2.59	2	NC*	Female	8.12	4	NC*
Total	8.82	8	91	Total	14.85	10	67
Hodgkin's Dise				<u>rostate</u>			
Male	2.68	4	NC*	Male	109.45	104	95
Female	2.27	3	NC*				
Total	4.95	7	141				
Kidney and Re	·			tomach_			
Male	10.58	10	95	Male	8.10	8	99
Female	6.97	6	86	Female	5.74	7	122
Total	17.55	16	91	Total	13.85	15	108
<u>Larynx</u>	. = 0	_	_	<u>estis</u>	• 00		
Male	6.70	7	104	Male	3.88	3	NC*
Female	1.97	4	NC*				
Total	8.67	11	127				
<u>Leukemia</u>	7.10	7		<u>hyroid</u>	1.70	0	NICH
Male	7.12	7	98	Male	1.70	0	NC*
Female	5.96	4	NC*	Female	4.87	7	144
Total	13.09	11 December	84	Total	6.57	7	107
Liver and Intra	_		· · · · · · · · · · · · · · · · · · ·	teri, Corpus	s and Uterus	NUS	
Male	2.99	2	NC*	Eores 1	21.00	20	01
Female	1.52	1	NC*	Female	21.89	20	91
Total	4.51	3	NC*	11 Cit og / T	nog		
Lung and Brone Male	<u>cnus</u> 59.84	61		<u>ll Sites / Ty</u> Male		370	102
Female		45	102 99		364.02 360.83		
	45.44			Female Total	369.83	382 752	103
Total	105.27	106	101	Total	733.85	752	102

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

STOUGHTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	20.77	20	96	Male	10.90	9	83	
Female	7.68	4	NC*	Female	9.06	9	99	
Total	28.45	24	84	Total	19.95	18	90	
Brain and Cen	tral Nervous	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	7.24	3	NC*	Male	3.76	7	186	
Female	6.90	6	87	Female	3.45	4	NC*	
Total	14.14	9	64	Total	7.21	11	152	
Breast			<u>N</u> e	on-Hodgkin'	s Lymphoma	<u>a</u>		
Male	1.11	0	NC*	Male	15.66	7	45 #-	
Female	126.94	157	124 #+	Female	13.88	24	173 #+	
Total	128.05	157	123 #+	Total	29.54	31	105	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	14.35	6	42 #-	
Female	8.34	6	72	Female	6.41	4	NC*	
				Total	20.76	10	48 #-	
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	55.08	54	98					
Female	50.97	53	104	Female	15.46	20	129	
Total	106.05	107	101					
Esophagus			<u>Pa</u>	ancreas				
Male	7.17	6	84	Male	7.65	10	131	
Female	2.54	5	197	Female	8.08	12	148	
Total	9.70	11	113	Total	15.73	22	140	

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Hodgkin's Di	odgkin's Disease				Prostate			
Male	3.37	4	NC*	Male	121.91	115	94	
Female	2.77	3	NC*					
Total	6.14	7	114					
Kidney and R	Renal Pelvis		9	Stomach				
Male	12.26	13	106	Male	9.15	8	87	
Female	7.42	8	108	Female	5.57	8	144	
Total	19.68	21	107	Total	14.72	16	109	
<u>Larynx</u>				<u>Testis</u>				
Male	7.74	7	90	Male	4.98	10	201	
Female	2.17	2	NC*					
Total	9.91	9	91					
<u>Leukemia</u>			, -	Thyroid				
Male	8.36	6	72	Male	2.09	1	NC*	
Female	6.37	6	94	Female	5.83	8	137	
Total	14.73	12	81	Total	7.92	9	114	
Liver and Int	<u>rahepatic Bi</u>	le Ducts]	<u>Uteri, Corp</u> ı	<u>is and Uter</u>	us, NOS		
Male	3.44	3	NC*					
Female	1.56	1	NC*	Female	23.83	27	113	
Total	5.00	4	NC*					
Lung and Bro	<u>nchus</u>		4	All Sites / T	<u>ypes</u>			
Male	68.09	78	115	Male	414.47	401	97	
Female	48.32	63	130 #+	Female	391.89	461	118 ^+	
Total	116.42	141	121 #+	Total	806.36	862	107	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

STOW

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

Exp Obs SIR Exp Obs SIR

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Bladder, Urinar	<u>y</u>		<u>M</u>	lelanoma of	<u>Skin</u>		
Male	3.23	0	NC*	Male	2.02	1	NC*
Female	1.11	0	NC*	Female	1.61	6	373 #+
Total	4.33	0	NC*	Total	3.63	7	193
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	1.41	1	NC*	Male	0.61	1	NC*
Female	1.19	0	NC*	Female	0.51	1	NC*
Total	2.60	1	NC*	Total	1.12	2	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>1</u>	
Male	0.19	0	NC*	Male	2.78	2	NC*
Female	21.65	21	97	Female	2.13	0	NC*
Total	21.84	21	96	Total	4.91	2	NC*
Cervix Uteri			<u>o</u>	ral Cavity ar	nd Pharynx		
				Male	2.80	1	NC*
Female	1.55	1	NC*	Female	1.06	3	NC*
				Total	3.86	4	NC*
Colon / Rectum	•		<u>o</u>	<u>vary</u>			
Male	8.59	4	NC*				
Female	7.11	7	98	Female	2.71	4	NC*
Total	15.70	11	70				
Esophagus			<u>Pa</u>	ancreas			
Male	1.29	0	NC*	Male	1.29	2	NC*
Female	0.35	0	NC*	Female	1.15	0	NC*
Total	1.64	0	NC*	Total	2.43	2	NC*
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>			
Male	0.67	1	NC*	Male	18.48	23	124
Female	0.51	0	NC*				
Total	1.18	1	NC*				
Kidney and Rei	nal Pelvis		<u>St</u>	omach_			
Male	2.24	3	NC*	Male	1.45	0	NC*
Female	1.18	1	NC*	Female	0.78	0	NC*
Total	3.42	4	NC*	Total	2.23	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.46	0	NC*	Male	0.99	0	NC*
Female	0.38	0	NC*				
Total	1.83	0	NC*				
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>			
Male	1.49	0	NC*	Male	0.42	1	NC*
Female	1.03	2	NC*	Female	1.10	3	NC*
Total	2.52	2	NC*	Total	1.52	4	NC*
Liver and Intra	<u>hepatic Bile l</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.60	0	NC*				
Female	0.23	0	NC*	Female	4.04	8	198
Total	0.83	0	NC*				

Lung and Bronchus			All Sites / Types					
Male	11.65	6	52	Male	68.67	49	71 #-	
Female	7.56	7	93	Female	63.26	65	103	
Total	19.20	13	68	Total	131.94	114	86	

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

STURBRIDGE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary	<u>-</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	5.88	5	85	Male	3.11	2	NC*
Female	1.87	2	NC*	Female	2.34	4	NC*
Total	7.75	7	90	Total	5.45	6	110
Brain and Centr	<u>al Nervous</u>	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>		
Male	2.11	1	NC*	Male	1.07	0	NC*
Female	1.83	2	NC*	Female	0.86	1	NC*
Total	3.93	3	NC*	Total	1.93	1	NC*
Breast			No	on-Hodgkin's	s Lymphoma	<u>1</u>	
Male	0.32	0	NC*	Male	4.45	5	112
Female	32.88	38	116	Female	3.48	6	173
Total	33.20	38	114	Total	7.92	11	139
Cervix Uteri			<u>O</u> :	ral Cavity an	<u>d Pharynx</u>		
				Male	4.21	3	NC*
Female	2.18	0	NC*	Female	1.65	1	NC*
				Total	5.85	4	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	15.68	17	108				
Female	12.22	17	139	Female	4.04	7	173
Total	27.90	34	122				

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Esophagus			<u>Pa</u>	ancreas			
Male	2.09	2	NC*	Male	2.22	2	NC*
Female	0.61	1	NC*	Female	2.00	1	NC*
Total	2.71	3	NC*	Total	4.22	3	NC*
Hodgkin's Dis	<u>ease</u>		<u>P1</u>	<u>rostate</u>			
Male	0.94	4	NC*	Male	35.81	37	103
Female	0.74	0	NC*				
Total	1.68	4	NC*				
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	3.60	5	139	Male	2.58	2	NC*
Female	1.94	0	NC*	Female	1.30	0	NC*
Total	5.54	5	90	Total	3.88	2	NC*
<u>Larynx</u>		<u>Testis</u>					
Male	2.30	0	NC*	Male	1.33	0	NC*
Female	0.58	0	NC*				
Total	2.88	0	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	2.41	2	NC*	Male	0.59	0	NC*
Female	1.62	1	NC*	Female	1.53	1	NC*
Total	4.04	3	NC*	Total	2.12	1	NC*
Liver and Intr	ahepatic Bile	Ducts	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
Male	1.00	1	NC*				
Female	0.39	0	NC*	Female	6.28	4	NC*
Total	1.40	1	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	20.08	19	95	Male	120.11	118	98
Female	12.83	9	70	Female	100.15	101	101
Total	32.90	28	85	Total	220.27	219	99

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SUDBURY

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Cancer Incidence by Sex, 1990 - 1995 Expected and Observed Case Counts, with Standardized Incidence Ratios

Dladday II-ina	Exp	<u>Obs</u>	SIR	Islamanna af	Exp	Obs	SIR
Bladder, Urina		_		Ielanoma of		10	100
Male	8.90	5	56	Male	5.29	10	189
Female	2.91	3	NC*	Female	4.16	9	217
Total	11.82	8	68 N	Total	9.44	19	201 ~+
Brain and Cent			· · · · · · · · · · · · · · · · · · ·	<u>Iultiple Mye</u>		2	NC*
Male	3.63	6	165	Male	1.65	2	NC*
Female	3.12	2	NC*	Female	1.35	1	NC*
Total	6.75	8	119	Total	3.00	3	NC*
<u>Breast</u>	0.51	0			s Lymphoma		104
Male	0.51	2	NC*	Male	7.25	9	124
Female	57.03	85	149 ^+	Female	5.57	7	126
Total	57.53	87	151 ^+	Total	12.82	16	125
<u>Cervix Uteri</u>			<u>O</u>	ral Cavity a		-	
.	204	4	Mark	Male	7.46	5	67
Female	3.94	4	NC*	Female	2.80	1	NC*
~			_	Total	10.26	6	58
Colon / Rectum				<u>vary</u>			
Male	23.67	19	80			_	
Female	18.67	24	129	Female	7.11	7	99
Total	42.33	43	102				
Esophagus			· · · · · · · · · · · · · · · · · · ·	<u>ancreas</u>			
Male	3.51	5	143	Male	3.51	2	NC*
Female	0.93	1	NC*	Female	3.03	7	231
Total	4.43	6	135	Total	6.54	9	138
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.61	1	NC*	Male	51.90	69	133 #+
Female	1.26	1	NC*				
Total	2.87	2	NC*				
Kidney and Re	<u>nal Pelvis</u>		<u>St</u>	tomach_			
Male	6.00	11	183	Male	3.97	1	NC*
Female	3.12	2	NC*	Female	2.05	3	NC*
Total	9.12	13	143	Total	6.01	4	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	3.95	1	NC*	Male	2.26	2	NC*
Female	1.01	0	NC*				
Total	4.96	1	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	3.93	5	127	Male	1.04	1	NC*
Female	2.70	3	NC*	Female	2.77	7	253 #+

Total	6.63	8	121	Total	3.80	8	210		
Liver and Intrahepatic Bile Ducts			<u>U</u> 1	t <mark>eri, Corpus</mark>	and Uterus	, NOS			
Male	1.63	0	NC*						
Female	0.61	0	NC*	Female	10.77	7	65		
Total	2.24	0	NC*						
Lung and Broi	<u>nchus</u>		<u>A</u>]	All Sites / Types					
Male	31.85	21	66	Male	186.82	196	105		
Female	20.16	18	89	Female	166.41	207	124 ~+		
Total	52.01	39	75	Total	353.23	403	114 #+		

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

SUNDERLAND

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>	Melanoma of Skin							
Male	1.48	1	NC*	Male	0.97	4	NC*		
Female	0.60	1	NC*	Female	0.93	0	NC*		
Total	2.08	2	NC*	Total	1.90	4	NC*		
Brain and Cen	tral Nervous	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>				
Male	0.71	0	NC*	Male	0.27	1	NC*		
Female	0.64	0	NC*	Female	0.26	1	NC*		
Total	1.35	0	NC*	Total	0.53	2	NC*		
Breast			<u>N</u>	on-Hodgkin'	s Lymphom	<u>a</u>			
Male	0.08	0	NC*	Male	1.44	0	NC*		
Female	10.74	10	93	Female	1.19	1	NC*		
Total	10.82	10	92	Total	2.63	1	NC*		
Cervix Uteri		Oral Cavity and Pharynx							
				Male	1.16	0	NC*		
Female	0.99	1	NC*	Female	0.52	0	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Total	1.68	0	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	3.93	4	NC*				
Female	4.01	1	NC*	Female	1.39	2	NC*
Total	7.94	5	63				
Esophagus			<u>Pa</u>	ancreas			
Male	0.52	0	NC*	Male	0.57	0	NC*
Female	0.19	1	NC*	Female	0.61	0	NC*
Total	0.71	1	NC*	Total	1.18	0	NC*
Hodgkin's Dise	<u>isease</u> <u>Prostate</u>						
Male	0.45	0	NC*	Male	8.41	4	NC*
Female	0.39	0	NC*				
Total	0.84	0	NC*				
Kidney and Ren	<u>nal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	0.95	0	NC*	Male	0.67	0	NC*
Female	0.58	0	NC*	Female	0.46	0	NC*
Total	1.53	0	NC*	Total	1.13	0	NC*
<u>Larynx</u>				<u>estis</u>			
Male	0.58	0	NC*	Male	0.80	0	NC*
Female	0.15	0	NC*				
Total	0.73	0	NC*				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	0.73	0	NC*	Male	0.25	0	NC*
Female	0.59	2	NC*	Female	0.74	0	NC*
Total	1.33	2	NC*	Total	0.99	0	NC*
Liver and Intra	<u>hepatic Bile D</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.26	0	NC*				
Female	0.12	0	NC*	Female	1.82	2	NC*
Total	0.39	0	NC*				
Lung and Brono	<u>All Sites / Types</u>						
Male	4.90	5	102	Male	31.66	21	66
Female	3.44	3	NC*	Female	32.79	26	79
Total	8.34	8	96	Total	64.45	47	73 #-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SUTTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>	
<u>Bladder, Urina</u> ı	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	4.71	4	NC*	Male	2.65	2	NC*	
Female	1.39	1	NC*	Female	1.95	2	NC*	
Total	6.11	5	82	Total	4.59	4	NC*	
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	1.83	2	NC*	Male	0.87	2	NC*	
Female	1.49	2	NC*	Female	0.64	1	NC*	
Total	3.32	4	NC*	Total	1.51	3	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>ı</u>		
Male	0.26	0	NC*	Male	3.76	4	NC*	
Female	26.06	22	84	Female	2.68	2	NC*	
Total	26.32	22	84	Total	6.43	6	93	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	3.58	3	NC*	
Female	1.88	0	NC*	Female	1.28	1	NC*	
				Total	4.86	4	NC*	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	12.54	10	80					
Female	9.09	9	99	Female	3.27	2	NC*	
Total	21.63	19	88					
Esophagus			<u>Pa</u>	ancreas				
Male	1.73	1	NC*	Male	1.80	0	NC*	
Female	0.45	0	NC*	Female	1.46	1	NC*	
Total	2.18	1	NC*	Total	3.26	1	NC*	
Hodgkin's Dise	ease		<u>P</u> 1	<u>rostate</u>				
Male	0.86	2	NC*	Male	27.67	22	80	
Female	0.66	0	NC*					
Total	1.51	2	NC*					
Kidney and Re	nal Pelvis		St	<u>omach</u>				
Male	3.00	1	NC*	Male	2.08	0	NC*	
Female	1.47	2	NC*	Female	0.99	1	NC*	
Total	4.47	3	NC*	Total	3.08	1	NC*	
<u>Larynx</u>				<u>estis</u>				
Male	1.90	3	NC*	Male	1.24	2	NC*	

Female	0.45	0	NC*					
Total	2.35	3	NC*					
Leukemia			<u>Tì</u>	<u>nyroid</u>				
Male	2.05	2	NC*	Male	0.53	0	NC*	
Female	1.33	1	NC*	Female	1.35	0	NC*	
Total	3.38	3	NC*	Total	1.87	0	NC*	
Liver and Intr	ahepatic Bile I	<u>Ducts</u>	<u>Uteri, Corpus and Uterus, NOS</u>					
Male	0.82	0	NC*					
Female	0.30	0	NC*	Female	4.85	8	165	
Total	1.12	0	NC*					
Lung and Broi	<u>nchus</u>		<u>A</u> l	ll Sites / Ty	pes			
Male	16.19	11	68	Male	97.04	77	79 #-	
Female	9.38	7	75	Female	77.86	70	90	
Total	25.57	18	70	Total	174.89	147	84 #-	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

SWAMPSCOTT

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		$\underline{\mathbf{Exp}}$	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary			<u>M</u>	elanoma of			
Male	13.29	14	105	Male	6.36	13	204 #+
Female	5.29	10	189	Female	5.34	11	206 #+
Total	18.58	24	129	Total	11.71	24	205 ~+
Brain and Central Nervous System			<u>M</u>	ultiple Mye			
Male	4.06	6	148	Male	2.39	2	NC*
Female	4.09	4	NC*	Female	2.32	2	NC*
Total	8.15	10	123	Total	4.72	4	NC*
Breast		Non-Hodgkin's Lymphoma					
Male	0.69	0	NC*	Male	9.18	17	185 #+

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	78.25	96	123	Female	9.06	11	121	
Total	78.94	96	122	Total	18.24	28	154 #+	
Cervix Uteri		Oral Cavity and Pharynx						
				Male	8.48	7	83	
Female	4.61	0	NC*	Female	4.04	4	NC*	
				Total	12.52	11	88	
Colon / Rectun	<u>n</u>		<u>O</u>	<u>vary</u>				
Male	35.24	34	96					
Female	35.77	32	89	Female	9.29	9	97	
Total	71.01	66	93					
Esophagus			<u>Pa</u>	ancreas				
Male	4.43	2	NC*	Male	4.78	8	167	
Female	1.77	1	NC*	Female	5.55	5	90	
Total	6.20	3	NC*	Total	10.32	13	126	
Hodgkin's Disease Prostate								
Male	1.65	2	NC*	Male	78.88	89	113	
Female	1.45	1	NC*					
Total	3.10	3	NC*					
Kidney and Ro	<u>enal Pelvis</u>		<u>St</u>	<u>omach</u>				
Male	7.45	9	121	Male	5.80	5	86	
Female	4.69	4	NC*	Female	3.95	3	NC*	
Total	12.14	13	107	Total	9.75	8	82	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	4.71	2	NC*	Male	2.21	1	NC*	
Female	1.32	1	NC*					
Total	6.02	3	NC*					
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>				
Male	4.95	4	NC*	Male	1.09	1	NC*	
Female	4.01	3	NC*	Female	3.15	2	NC*	
Total	8.95	7	78	Total	4.24	3	NC*	
Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>					
Male	2.11	1	NC*					
Female	1.03	2	NC*	Female	14.67	17	116	
Total	3.14	3	NC*					
Lung and Bron	<u>ichus</u>		<u>A</u>]	ll Sites / Ty	pes			
Male	42.70	33	77	Male	258.11	273	106	
Female	30.52	36	118	Female	249.02	281	113 #+	
Total	73.22	69	94	Total	507.13	554	109 #+	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

SWANSEA

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinary			<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	12.85	16	125	Male	6.64	3	NC*	
Female	4.36	6	138	Female	5.05	3	NC*	
Total	17.21	22	128	Total	11.69	6	51	
Brain and Central Nervous System		Multiple Myeloma						
Male	4.41	4	NC*	Male	2.32	0	NC*	
Female	3.90	5	128	Female	1.97	1	NC*	
Total	8.31	9	108	Total	4.30	1	NC*	
<u>Breast</u>			Non-Hodgkin's Lymphoma					
Male	0.69	1	NC*	Male	9.47	5	53	
Female	72.12	73	101	Female	7.84	10	128	
Total	72.81	74	102	Total	17.31	15	87	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	8.96	7	78	
Female	4.58	3	NC*	Female	3.66	4	NC*	
				Total	12.62	11	87	
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	34.15	17	50 ~-					
Female	28.82	27	94	Female	8.75	9	103	
Total	62.98	44	70 #-					
Esophagus		<u>Pancreas</u>						
Male	4.50	5	111	Male	4.79	9	188	
Female	1.44	0	NC*	Female	4.61	8	174	
Total	5.94	5	84	Total	9.40	17	181 #+	
Hodgkin's Dis	ease		<u>Pı</u>	<u>rostate</u>				
Male	1.91	3	NC*	Male	77.22	59	76 #-	
Female	1.49	2	NC*					
Total	3.40	5	147					
Kidney and Ro	enal Pelvis		<u>St</u>	omach_				
Male	7.66	10	131	Male	5.63	6	106	

Female	4.25	5	118	Female	3.12	1	NC*	
Total	11.91	15	126	Total	8.76	7	80	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	4.90	4	NC*	Male	2.68	5	186	
Female	1.26	0	NC*					
Total	6.16	4	NC*					
<u>Leukemia</u>		<u>Thyroid</u>						
Male	5.12	5	98	Male	1.22	0	NC*	
Female	3.57	3	NC*	Female	3.17	2	NC*	
Total	8.70	8	92	Total	4.39	2	NC*	
Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>					
Male	2.15	2	NC*					
Female	0.89	0	NC*	Female	13.70	13	95	
TD 4 1								
Total	3.03	2	NC*					
Lung and Bron		2		ll Sites / Ty	<u>pes</u>			
		2 52		ll Sites / Ty Male	pes_ 258.14	230	89	
Lung and Bron	chus		<u>A</u>]				89 96	
Lung and Bron Male	<u>chus</u> 42.97	52	<u>Al</u> 121	Male	258.14	230		

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels